<html lang="en" class="pb-page js" data-request-id="94d6f09145da00fb-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6f09145da00fb-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/WKH5544M-MCnnQ5vymp0L7tcC2v3xc597tU_JesbSiA45TWo99-NNj8NroIFG-xXSMm72xIqBxWHTiuNQ0JPoA=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6f09145da00fb-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.017437085425222154"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="Specialties" content="Allergy/Immunology|Dermatology|Clinical Medicine|Pediatrics">
<meta name="topics" content="Inflammatory Disease|Autoimmune Disease|Dermatology General|Clinical Medicine General|Adolescent Medicine|Allergy/Immunology General">
<meta name="articleCategory" content="Research"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2118828","title":"Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo","category":"Research","type":"Original Article","topics":"Inflammatory Disease|Autoimmune Disease|Dermatology General|Clinical Medicine General|Adolescent Medicine|Allergy/Immunology General","specialties":"Allergy/Immunology|Dermatology|Clinical Medicine|Pediatrics","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-10-20T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Allergy/Immunology|Dermatology|Clinical Medicine|Pediatrics\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Inflammatory Disease|Autoimmune Disease|Dermatology General|Clinical Medicine General|Adolescent Medicine|Allergy/Immunology General\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2118828","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Quick Take","title":"Ruxolitinib Cream for Vitiligo","doi":"10.1056/NEJMdo006719","issueDate":"2022-10-20T00:00Z","age":"6Months-1990","isFree":"n","topics":"Inflammatory Disease|Autoimmune Disease|Dermatology General|Clinical Medicine General|Adolescent Medicine|Allergy/Immunology General","viewType":"Full","specialties":"Allergy/Immunology|Dermatology|Clinical Medicine|Pediatrics"},{"type":"Research Summary","title":"Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo","doi":"10.1056/NEJMdo006720","issueDate":"2022-10-20T00:00Z","age":"6Months-1990","isFree":"n","topics":"Inflammatory Disease|Autoimmune Disease|Dermatology General|Clinical Medicine General|Adolescent Medicine|Allergy/Immunology General","viewType":"Full","specialties":"Allergy/Immunology|Dermatology|Clinical Medicine|Pediatrics"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6f09145da00fb-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo"><meta name="dc.Creator" content="David Rosmarin"><meta name="dc.Creator" content="Thierry Passeron"><meta name="dc.Creator" content="Amit G. Pandya"><meta name="dc.Creator" content="Pearl Grimes"><meta name="dc.Creator" content="John E. Harris"><meta name="dc.Creator" content="Seemal R. Desai"><meta name="dc.Creator" content="Mark Lebwohl"><meta name="dc.Creator" content="Mireille Ruer-Mulard"><meta name="dc.Creator" content="Julien Seneschal"><meta name="dc.Creator" content="Albert Wolkerstorfer"><meta name="dc.Creator" content="Deanna Kornacki"><meta name="dc.Creator" content="Kang Sun"><meta name="dc.Creator" content="Kathleen Butler"><meta name="dc.Creator" content="Khaled Ezzedine"><meta name="dc.Description" content="Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial inv..."><meta name="Description" content="Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial inv..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-10-20"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2118828"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202210203871606"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2211886"><meta name="dc.Relation" content="YXQYoa2118828"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2118828">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2118828">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2118828">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo | NEJM">
        <meta property="og:title" content="Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2118828">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/dbb9ea1e-44ab-468b-a14e-93993bfebe48/nejmoa2118828_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/dbb9ea1e-44ab-468b-a14e-93993bfebe48/nejmoa2118828_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream
formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation
in a phase 2 trial inv...">
        <meta name="twitter:description" content="Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream
formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation
in a phase 2 trial inv...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2118828">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2118828">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2022.387.issue-16;article:article:doi\:10.1056/NEJMoa2118828;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2118828" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2118828" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2118828" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2118828" class="inputDoi"><input type="hidden" value="D. Rosmarin and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;387:1445-1455" class="inputCitation"><input type="hidden" value="10-19-2022" class="inputEPubDate"><input type="hidden" value="October 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6f09145da00fb-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">David</span> <span property="familyName">Rosmarin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thierry</span> <span property="familyName">Passeron</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-0797-6570" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-0797-6570</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Amit G.</span> <span property="familyName">Pandya</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pearl</span> <span property="familyName">Grimes</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">John E.</span> <span property="familyName">Harris</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Seemal R.</span> <span property="familyName">Desai</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mark</span> <span property="familyName">Lebwohl</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+7</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mireille</span> <span property="familyName">Ruer-Mulard</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Julien</span> <span property="familyName">Seneschal</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Albert</span> <span property="familyName">Wolkerstorfer</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Deanna</span> <span property="familyName">Kornacki</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kang</span> <span property="familyName">Sun</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kathleen</span> <span property="familyName">Butler</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Khaled</span> <span property="familyName">Ezzedine</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the TRuE-V Study Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-7</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">October 19, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">387</span></span>:<span property="pageStart">1445</span>-<span property="pageEnd">1455</span></div><div class="doi">DOI: 10.1056/NEJMoa2118828</div><div class="core-enumeration"><a href="/toc/nejm/387/16"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">387</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">16</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DDavid%2BRosmarin%252C%2BThierry%2BPasseron%252C%2BAmit%2BG.%2BPandya%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D16%26contentID%3D10.1056%252FNEJMoa2118828%26title%3DTwo%2BPhase%2B3%252C%2BRandomized%252C%2BControlled%2BTrials%2Bof%2BRuxolitinib%2BCream%2Bfor%2BVitiligo%26publicationDate%3D10%252F20%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2118828" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DDavid%2BRosmarin%252C%2BThierry%2BPasseron%252C%2BAmit%2BG.%2BPandya%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D16%26contentID%3D10.1056%252FNEJMoa2118828%26title%3DTwo%2BPhase%2B3%252C%2BRandomized%252C%2BControlled%2BTrials%2Bof%2BRuxolitinib%2BCream%2Bfor%2BVitiligo%26publicationDate%3D10%252F20%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/7f5e23f8-a36e-40a0-b163-a9684aa19d47/nejmoa2118828.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2118828.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2118828" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2118828" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2118828.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted two phase 3, double-blind, vehicle-controlled trials (Topical Ruxolitinib Evaluation in Vitiligo Study 1 [TRuE-V1] and 2 [TRuE-V2]) in North America and Europe that involved patients 12 years of age or older who had nonsegmental vitiligo with depigmentation covering 10% or less of total body-surface area. Patients were randomly assigned in a 2:1 ratio to apply 1.5% ruxolitinib cream or vehicle control twice daily for 24 weeks to all vitiligo areas on the face and body, after which all patients could apply 1.5% ruxolitinib cream through week 52. The primary end point was a decrease (improvement) of at least 75% from baseline in the facial Vitiligo Area Scoring Index (F-VASI; range, 0 to 3, with higher scores indicating a greater area of facial depigmentation), or F-VASI75 response, at week 24. There were five key secondary end points, including improved responses on the Vitiligo Noticeability Scale.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2118828_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2118828_f0.jpg"><img src="/cms/10.1056/NEJMoa2118828/asset/dbb9ea1e-44ab-468b-a14e-93993bfebe48/assets/images/large/nejmoa2118828_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 674 patients were enrolled, 330 in TRuE-V1 and 344 in TRuE-V2. In TRuE-V1, the percentage of patients with an F-VASI75 response at week 24 was 29.8% in the ruxolitinib-cream group and 7.4% in the vehicle group (relative risk, 4.0; 95% confidence interval [CI], 1.9 to 8.4; P&lt;0.001). In TRuE-V2, the percentages were 30.9% and 11.4%, respectively (relative risk, 2.7; 95% CI, 1.5 to 4.9; P&lt;0.001). The results for key secondary end points showed superiority of ruxolitinib cream over vehicle control. Among patients who applied ruxolitinib cream throughout 52 weeks, adverse events occurred in 54.8% in TRuE-V1 and 62.3% in TRuE-V2; the most common adverse events were application-site acne (6.3% and 6.6%, respectively), nasopharyngitis (5.4% and 6.1%), and application-site pruritus (5.4% and 5.3%).</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In two phase 3 trials, application of ruxolitinib cream resulted in greater repigmentation of vitiligo lesions than vehicle control through 52 weeks, but it was associated with acne and pruritus at the application site. Larger and longer trials are required to determine the effect and safety of ruxolitinib cream in patients with vitiligo. (Funded by Incyte; TRuE-V1 and TRuE-V2 ClinicalTrials.gov numbers, <a href="http://clinicaltrials.gov/show/NCT04052425" target="_blank">NCT04052425</a> and <a href="http://clinicaltrials.gov/show/NCT04057573" target="_blank">NCT04057573</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006719/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/2e4e9afa-9b6e-4152-85bc-8b14bcca8cf4/media/NEJMdo006719_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006719/full/" class="ng-do-media_item-title-link">Ruxolitinib Cream for Vitiligo</a>
            </h6>
            <div class="ng-do-media_item-duration">1m 55s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Vitiligo is a chronic autoimmune disease that results in skin depigmentation<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2-1" href-manipulated="true">1,2</a></sup> and reduced quality of life.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4-1" href-manipulated="true">3,4</a></sup> Quality-of-life burden is affected by a high prevalence of psychosocial coexisting conditions among patients with vitiligo and is further affected by factors including lesion visibility (e.g., face and hand involvement) and extensive body-area involvement.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-2" href-manipulated="true" aria-label="Reference 4">4</a></sup> Skin lesions are characterized by white patches corresponding with a loss of functioning melanocytes in the epidermis.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2-2" href-manipulated="true">1,2</a></sup> Interferon-γ plays an important role in vitiligo pathogenesis and signals through the Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway,<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6" id="body-ref-r6-1" href-manipulated="true">5,6</a></sup> leading to up-regulation of C-X-C motif chemokine ligand 10 (CXCL10) and promoting CD8+ T-cell recruitment, which drives melanocyte destruction.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6 r7 r8 r9 r10 r11 r12" id="body-ref-r12" href-manipulated="true">5-12</a></sup> At the time we collected and analyzed the data reported here, there were no approved treatments for repigmentation of vitiligo lesions in the United States or Europe.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup></div><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Small studies have provided evidence for repigmentation in patients with vitiligo after treatment with JAK inhibitors.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15 r16" id="body-ref-r16" href-manipulated="true">14-16</a></sup> A cream formulation of ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and 2 (JAK2), resulted in repigmentation over 52 weeks in a phase 2, dose-ranging, randomized trial involving adults with vitiligo.</span><sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-1" href-manipulated="true" aria-label="Reference 17">17</a></sup> Among patients who applied 1.5% ruxolitinib cream twice daily, 45% had at least a 50% decrease (improvement) from baseline in the facial Vitiligo Area Scoring Index (F-VASI) at week 24 (primary end point), and 30% had a decrease of at least 75%, with improvement through week 52.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-2" href-manipulated="true" aria-label="Reference 17">17</a></sup> We conducted two phase 3 trials of ruxolitinib cream (Topical Ruxolitinib Evaluation in Vitiligo Study 1 [TRuE-V1] and 2 [TRuE-V2]) in adolescents and adults with nonsegmental vitiligo.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Oversight</h3><div role="paragraph">The trial <a href="#ap1">protocols</a> (available with the full text of this article at NEJM.org) were approved by an institutional review board or ethics committee at participating centers. The trials were conducted in accordance with the Declaration of Helsinki and adhered to Good Clinical Practice guidelines and applicable country-specific laws and regulations. Written informed consent or assent was provided by all the patients. Incyte sponsored the trials; it provided the active trial drug and matching vehicle cream (without active ingredient), participated in trial design, and collaborated with the authors in analyzing and interpreting the data and writing and approving the manuscript. The authors prepared the manuscript, with medical writing assistance funded by the sponsor. All the authors vouch for the accuracy and completeness of the data and for the adherence of the trials to the protocols. Agreements that required investigators to maintain data confidentiality were in place between the sponsor and the authors. The sponsor could not delay or interdict publication of the results of the trials.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">Eligible patients, who were recruited at participating trial centers, were 12 years of age or older and had received a diagnosis of nonsegmental vitiligo with depigmented areas covering 10% or less of total body-surface area, including at least 0.5% of body-surface area on the face and at least 3% of body-surface area on nonfacial areas. Patients were also required to have scores of 0.5 or higher on the F-VASI (range, 0 to 3, with higher scores representing a greater area of facial depigmentation across the forehead to original hairline, cheeks to jawline vertically and laterally from corner of mouth to tragus, nose, and eyelids) and scores of 3 or higher on the total Vitiligo Area Scoring Index (T-VASI; range, 0 to 100, with higher scores indicating a greater area of total body depigmentation across the head or neck, including the scalp; trunk, including genitalia; upper limbs, including axillae; hands; lower limbs, including buttocks; and feet). The methods of calculating these measures are given below. Key exclusion criteria were the presence of complete leukotrichia within any facial lesions, dermatologic disease confounding vitiligo assessment, previous use of JAK inhibitor therapy, and use of the following therapies for vitiligo before baseline: any biologic or experimental therapy within 12 weeks (or 5 half-lives), phototherapy within 8 weeks, immunomodulating treatments within 4 weeks, or topical treatments within 1 week.</div></section><section id="sec-1-3"><h3>Trial Design</h3><div role="paragraph">These were two multinational, phase 3, double-blind, vehicle-controlled trials of identical design conducted across 101 centers (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org) in North America (United States and Canada) and Europe (Bulgaria, France, Germany, Italy, the Netherlands, Poland, and Spain). An interactive response technology system was used to manage enrollment, including assignment of patient trial numbers, tracking of visits, randomization according to prespecified characteristics, masking of trial-group assignments, and management of trial-drug inventory. Patients, who were stratified according to geographic region (North America or Europe) and Fitzpatrick skin type (I [pale white] or II [white] vs. III [light brown] to VI [deeply pigmented dark brown to black]), were randomly assigned in a 2:1 ratio to apply 1.5% ruxolitinib cream or matching vehicle cream twice daily to all depigmented vitiligo lesions on the face and body identified at trial entry for 24 weeks (Fig. S2). Patients and investigators remained unaware of the trial-group assignments throughout the trials; the sponsor was aware of the trial-group assignments after database lock for the primary analysis. After completion of the week 24 visit, all the patients could apply 1.5% ruxolitinib cream twice daily for an additional 28 weeks in an open-label treatment extension phase of the trials.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">The primary end point was a decrease (improvement) of at least 75% from baseline in the F-VASI (F-VASI75 response) at week 24. The Vitiligo Area Scoring Index integrates the body-surface area with a depigmentation score (i.e., taking into account lesion integrity as opposed to margins only). The F-VASI is a tool for calculating the surface area of vitiligo depigmentation on the face on the basis of the size of the patient’s palmar surface (i.e., the palm plus five digits), with degree of depigmentation estimated to the nearest percentage (0% [no depigmentation present], 10%, 25%, 50%, 75%, 90%, or 100% [no pigment present]), as detailed in the protocols.</div><div role="paragraph">Key secondary end points (all assessed at week 24) were a decrease of at least 50% in the F-VASI (F-VASI50 response), a decrease of at least 90% in the F-VASI (F-VASI90 response), a decrease of at least 50% in the T-VASI (T-VASI50 response), a Vitiligo Noticeability Scale (VNS) rating of a lot less noticeable or no longer noticeable (VNS response), and the percentage change from baseline in facial body-surface area affected by vitiligo. Other prespecified secondary end points included the safety and side-effect profile of ruxolitinib cream on the basis of monitoring of adverse events and laboratory data; the percentage change from baseline in the F-VASI, the T-VASI, facial body-surface area affected by vitiligo, and total body-surface area affected by vitiligo; the percentage of patients having F-VASI improvements (i.e., a decrease of ≥25% in the F-VASI [F-VASI25 response], F-VASI50 response, F-VASI75 response, and F-VASI90 response) or T-VASI improvements (i.e., a decrease of ≥25% in the T-VASI [T-VASI25 response], T-VASI50 response, T-VASI75 response, and T-VASI90 response); the percentage of patients in each VNS category; the change from baseline in the Dermatology Life Quality Index (DLQI [for adults])<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-1" href-manipulated="true" aria-label="Reference 18">18</a></sup> or the Children’s Dermatology Life Quality Index (CDLQI)<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19-1" href-manipulated="true" aria-label="Reference 19">19</a></sup> during treatment; and population-based trough plasma concentrations of ruxolitinib at weeks 4, 24, and 40.</div><div role="paragraph">Exploratory end points included the percentage of patients having a facial or total Physician’s Global Vitiligo Assessment (F-PhGVA and T-PhGVA, respectively; ranges, 0 to 4 on a Likert scale) of clear or almost clear (scores of 0 or 1; PhGVA response), the percentage of patients having a facial or total Patient’s Global Impression of Change–Vitiligo (F-PaGIC-V and T-PaGIC-V, respectively; ranges, 1 to 7 on a Likert scale) of very much or much improved (scores of 1 or 2; PaGIC-V response), and the percentage of patients in each category of PhGVA, PaGIC-V, and color-matching (excellent, very good, good, poor, or very poor) during treatment. (Details on end points are provided in the <a href="#ap2">Supplementary Appendix</a>.)</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">For each trial, a sample size of 300 patients was determined to provide sufficient statistical power (&gt;88%) to detect the difference between ruxolitinib cream and vehicle control in the primary and key secondary end points. The trials aimed to include a population comprising at least 10% adolescent patients (12 to 17 years of age) and at least 50% patients who were younger than 40 years of age to ensure fair representation of patients with vitiligo. Multiple imputation was applied to account for missing values in the analysis of primary and key secondary end points, as detailed in the statistical analysis plan, available with the protocols. The primary and key secondary end points were tested in a prespecified fixed sequence (F-VASI75 response, F-VASI50 response, F-VASI90 response, T-VASI50 response, VNS response, and percentage change from baseline in facial body-surface area affected by vitiligo, all at week 24) to control the rate of overall type I error with a two-sided alpha level of 0.05. Ruxolitinib cream and vehicle were compared with the use of exact logistic regression for binary end points, presented with relative risk, and were compared with the use of an analysis of covariance model for facial body-surface area affected by vitiligo. The relative risk was derived as the average of relative risks estimated from individual data sets multiply imputed, and the 95% confidence intervals for the relative risks are based on the pooled standard errors obtained with the use of Rubin’s method<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> and normal approximation. All other secondary and exploratory end points were reported as observed without adjustments for multiplicity, and analyses were summarized with the use of descriptive statistics.</div><div role="paragraph">The efficacy analysis used the modified intention-to-treat population: in TRuE-V1, all randomly assigned patients were included; in TRuE-V2, 13 patients from one trial site were excluded for nonadherence to the protocol, which resulted in data-quality concerns (sensitivity analyses were performed to determine the effect of site exclusion). All the patients who applied at least one dose of ruxolitinib cream or vehicle were included in the safety analyses (safety population). Adverse events during the double-blind period (up to week 24) are reported in the safety population (ruxolitinib-cream group and vehicle group); adverse events during the open-label treatment extension period (after week 24) are reported in the treatment-extension evaluable population (ruxolitinib-cream group and vehicle-to-ruxolitinib-cream group). The pharmacokinetic-evaluable population (up to week 24) included patients who applied at least one dose of ruxolitinib cream and provided at least one postdose blood sample.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patient Characteristics</h3><div role="paragraph">TRuE-V1 was conducted from September 20, 2019, to October 21, 2021, and TRuE-V2 was conducted from October 3, 2019, to October 1, 2021. TRuE-V1 enrolled 330 patients (221 patients in the ruxolitinib-cream group and 109 in the vehicle group) at 45 centers in North America (29 centers) and Europe (16). TRuE-V2 enrolled 344 patients (229 patients in the ruxolitinib-cream group and 115 in the vehicle group) at 49 centers in North America (32 centers) and Europe (17). TRuE-V1 included all 330 randomly assigned patients in the efficacy and safety analyses. TRuE-V2 included 331 patients in the efficacy analyses (13 patients were excluded for nonadherence to the protocol; sensitivity analyses including data from this site confirmed that removal of these data did not affect the interpretation of efficacy results) and 343 patients in the safety analyses (1 randomly assigned patient did not apply ≥1 dose of ruxolitinib cream and was excluded). In the safety populations, 286 patients (86.7%) in TRuE-V1 and 308 (89.8%) in TRuE-V2 completed the 24-week double-blind periods (Fig. S3). The primary reasons for discontinuation of the trial agent during the double-blind period were loss to follow-up (21 patients [6.4%] in TRuE-V1 and 16 [4.7%] in TRuE-V2) and withdrawal by the patient (17 patients [5.2%] and 11 [3.2%], respectively).</div><div role="paragraph">The mean (±SD) age of the patients in the safety populations was 40.2±15.9 years in TRuE-V1 and 38.9±14.3 years in TRuE-V2. A total of 10.9% of the patients in TRuE-V1 and 10.5% of those in TRuE-V2 were 12 to 17 years of age, and 54.5% and 57.1%, respectively, of the patients were 40 years of age or younger; 56.4% and 50.1%, respectively, of the patients were girls or women. The trials included patients of all Fitzpatrick skin types; 78.5% of the patients in TRuE-V1 and 65.9% of those in TRuE-V2 had skin types I, II, or III (pale white, white, or light brown skin), and 21.5% and 34.1%, respectively, had skin types IV, V, or VI (moderate brown, dark brown, or deeply pigmented dark brown to black skin). The distribution of baseline characteristics was similar across trial groups for both trials (<a href="#t1">Table 1</a>) and was representative of a population of patients who would apply topical treatment for vitiligo; however, 5% or fewer of the patients identified themselves as Black (see Table S1 for the representativeness of the patient population).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t1.jpg"><img src="/cms/10.1056/NEJMoa2118828/asset/a9e84a5a-74cb-40fa-a9d2-417c911ee071/assets/images/large/nejmoa2118828_t1.jpg" height="3438" width="1900" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>TRuE-V1</span></th><th class="txxr-borders" colspan="3"><span>TRuE-V2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Vehicle<br>(N=109)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=221)</th><th class="xxxx-borders">Total<br>(N=330)</th><th class="xxxx-borders">Vehicle<br>(N=115)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=228)</th><th class="xxxr-borders">Total<br>(N=343)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">39.7±16.7</td><td class="xxxx-borders shading">40.5±15.4</td><td class="xxxx-borders shading">40.2±15.9</td><td class="xxxx-borders shading">39.8±12.1</td><td class="xxxx-borders shading">38.4±15.2</td><td class="xxxr-borders shading">38.9±14.3</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Age group — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">12–17 yr</td><td class="xxxx-borders shading">11 (10.1)</td><td class="xxxx-borders shading">25 (11.3)</td><td class="xxxx-borders shading">36 (10.9)</td><td class="xxxx-borders shading">6 (5.2)</td><td class="xxxx-borders shading">30 (13.2)</td><td class="xxxr-borders shading">36 (10.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">18–64 yr</td><td class="xxxx-borders">85 (78.0)</td><td class="xxxx-borders">180 (81.4)</td><td class="xxxx-borders">265 (80.3)</td><td class="xxxx-borders">106 (92.2)</td><td class="xxxx-borders">186 (81.6)</td><td class="xxxr-borders">292 (85.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥65 yr</td><td class="xxxx-borders shading">13 (11.9)</td><td class="xxxx-borders shading">16 (7.2)</td><td class="xxxx-borders shading">29 (8.8)</td><td class="xxxx-borders shading">3 (2.6)</td><td class="xxxx-borders shading">12 (5.3)</td><td class="xxxr-borders shading">15 (4.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">50 (45.9)</td><td class="xxxx-borders">136 (61.5)</td><td class="xxxx-borders">186 (56.4)</td><td class="xxxx-borders">60 (52.2)</td><td class="xxxx-borders">112 (49.1)</td><td class="xxxr-borders">172 (50.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">96 (88.1)</td><td class="xxxx-borders">180 (81.4)</td><td class="xxxx-borders">276 (83.6)</td><td class="xxxx-borders">93 (80.9)</td><td class="xxxx-borders">182 (79.8)</td><td class="xxxr-borders">275 (80.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">11 (5.0)</td><td class="xxxx-borders shading">15 (4.5)</td><td class="xxxx-borders shading">5 (4.3)</td><td class="xxxx-borders shading">12 (5.3)</td><td class="xxxr-borders shading">17 (5.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">5 (2.3)</td><td class="xxxx-borders">9 (2.7)</td><td class="xxxx-borders">7 (6.1)</td><td class="xxxx-borders">12 (5.3)</td><td class="xxxr-borders">19 (5.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">2 (1.8)</td><td class="xxxx-borders shading">9 (4.1)</td><td class="xxxx-borders shading">11 (3.3)</td><td class="xxxx-borders shading">7 (6.1)</td><td class="xxxx-borders shading">19 (8.3)</td><td class="xxxr-borders shading">26 (7.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Not reported</td><td class="xxxx-borders">3 (2.8)</td><td class="xxxx-borders">16 (7.2)</td><td class="xxxx-borders">19 (5.8)</td><td class="xxxx-borders">3 (2.6)</td><td class="xxxx-borders">3 (1.3)</td><td class="xxxr-borders">6 (1.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Fitzpatrick skin type — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">I</td><td class="xxxx-borders">3 (2.8)</td><td class="xxxx-borders">10 (4.5)</td><td class="xxxx-borders">13 (3.9)</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxr-borders">3 (0.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">II</td><td class="xxxx-borders shading">40 (36.7)</td><td class="xxxx-borders shading">74 (33.5)</td><td class="xxxx-borders shading">114 (34.5)</td><td class="xxxx-borders shading">32 (27.8)</td><td class="xxxx-borders shading">57 (25.0)</td><td class="xxxr-borders shading">89 (25.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">III</td><td class="xxxx-borders">43 (39.4)</td><td class="xxxx-borders">89 (40.3)</td><td class="xxxx-borders">132 (40.0)</td><td class="xxxx-borders">45 (39.1)</td><td class="xxxx-borders">89 (39.0)</td><td class="xxxr-borders">134 (39.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">IV</td><td class="xxxx-borders shading">15 (13.8)</td><td class="xxxx-borders shading">34 (15.4)</td><td class="xxxx-borders shading">49 (14.8)</td><td class="xxxx-borders shading">25 (21.7)</td><td class="xxxx-borders shading">55 (24.1)</td><td class="xxxr-borders shading">80 (23.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">V</td><td class="xxxx-borders">7 (6.4)</td><td class="xxxx-borders">11 (5.0)</td><td class="xxxx-borders">18 (5.5)</td><td class="xxxx-borders">10 (8.7)</td><td class="xxxx-borders">17 (7.5)</td><td class="xxxr-borders">27 (7.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">VI</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">3 (1.4)</td><td class="xxxx-borders shading">4 (1.2)</td><td class="xxxx-borders shading">2 (1.7)</td><td class="xxxx-borders shading">8 (3.5)</td><td class="xxxr-borders shading">10 (2.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Geographic region — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">North America</td><td class="xxxx-borders shading">73 (67.0)</td><td class="xxxx-borders shading">147 (66.5)</td><td class="xxxx-borders shading">220 (66.7)</td><td class="xxxx-borders shading">83 (72.2)</td><td class="xxxx-borders shading">160 (70.2)</td><td class="xxxr-borders shading">243 (70.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Europe</td><td class="xxxx-borders">36 (33.0)</td><td class="xxxx-borders">74 (33.5)</td><td class="xxxx-borders">110 (33.3)</td><td class="xxxx-borders">32 (27.8)</td><td class="xxxx-borders">68 (29.8)</td><td class="xxxr-borders">100 (29.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">F-VASI<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">1.00±0.59</td><td class="xxxx-borders shading">0.93±0.58</td><td class="xxxx-borders shading">0.95±0.59</td><td class="xxxx-borders shading">0.83±0.52</td><td class="xxxx-borders shading">0.90±0.52</td><td class="xxxr-borders shading">0.88±0.52</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">T-VASI<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">6.42±1.92</td><td class="xxxx-borders">6.49±2.02</td><td class="xxxx-borders">6.47±1.99</td><td class="xxxx-borders">7.02±2.20</td><td class="xxxx-borders">6.84±2.06</td><td class="xxxr-borders">6.90±2.10</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Facial BSA affected by vitiligo — %<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">1.15±0.71</td><td class="xxxx-borders shading">1.05±0.69</td><td class="xxxx-borders shading">1.09±0.70</td><td class="xxxx-borders shading">0.92±0.57</td><td class="xxxx-borders shading">0.98±0.57</td><td class="xxxr-borders shading">0.96±0.57</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Total BSA affected by vitiligo — %</td><td class="xxxx-borders">7.22±2.01</td><td class="xxxx-borders">7.28±2.03</td><td class="xxxx-borders">7.26±2.02</td><td class="xxxx-borders">7.68±2.04</td><td class="xxxx-borders">7.44±2.01</td><td class="xxxr-borders">7.52±2.02</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Duration of disease — yr</td><td class="xxxx-borders shading">13.2±10.0</td><td class="xxxx-borders shading">13.9±11.7</td><td class="xxxx-borders shading">13.6±11.1</td><td class="xxxx-borders shading">16.0±11.6</td><td class="xxxx-borders shading">15.9±12.1</td><td class="xxxr-borders shading">15.9±11.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Received diagnosis in childhood — no. (%)</td><td class="xxxx-borders">34 (31.2)</td><td class="xxxx-borders">72 (32.6)</td><td class="xxxx-borders">106 (32.1)</td><td class="xxxx-borders">43 (37.4)</td><td class="xxxx-borders">96 (42.1)</td><td class="xxxr-borders">139 (40.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Disease stability — no. (%)<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stable</td><td class="xxxx-borders">80 (73.4)</td><td class="xxxx-borders">165 (74.7)</td><td class="xxxx-borders">245 (74.2)</td><td class="xxxx-borders">88 (76.5)</td><td class="xxxx-borders">166 (72.8)</td><td class="xxxr-borders">254 (74.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Progressive</td><td class="xxxx-borders shading">29 (26.6)</td><td class="xxxx-borders shading">56 (25.3)</td><td class="xxxx-borders shading">85 (25.8)</td><td class="xxxx-borders shading">27 (23.5)</td><td class="xxxx-borders shading">62 (27.2)</td><td class="xxxr-borders shading">89 (25.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Other autoimmune disorders — no. (%)<a href="#t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">18 (16.5)</td><td class="xxxx-borders">53 (24.0)</td><td class="xxxx-borders">71 (21.5)</td><td class="xxxx-borders">18 (15.7)</td><td class="xxxx-borders">37 (16.2)</td><td class="xxxr-borders">55 (16.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Thyroid disorders</td><td class="xxxx-borders shading">17 (15.6)</td><td class="xxxx-borders shading">50 (22.6)</td><td class="xxxx-borders shading">67 (20.3)</td><td class="xxxx-borders shading">15 (13.0)</td><td class="xxxx-borders shading">35 (15.4)</td><td class="xxxr-borders shading">50 (14.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Juvenile diabetes mellitus</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pernicious anemia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">5 (2.3)</td><td class="xxxx-borders">6 (1.8)</td><td class="xxxx-borders">6 (5.2)</td><td class="xxxx-borders">5 (2.2)</td><td class="xxxr-borders">11 (3.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Previous therapy — no. (%)<a href="#t1fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders shading">61 (56.0)</td><td class="xxxx-borders shading">131 (59.3)</td><td class="xxxx-borders shading">192 (58.2)</td><td class="xxxx-borders shading">76 (66.1)</td><td class="xxxx-borders shading">143 (62.7)</td><td class="xxxr-borders shading">219 (63.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Topical calcineurin inhibitors</td><td class="xxxx-borders">31 (28.4)</td><td class="xxxx-borders">72 (32.6)</td><td class="xxxx-borders">103 (31.2)</td><td class="xxxx-borders">37 (32.2)</td><td class="xxxx-borders">74 (32.5)</td><td class="xxxr-borders">111 (32.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Topical glucocorticoids</td><td class="xxxx-borders shading">28 (25.7)</td><td class="xxxx-borders shading">67 (30.3)</td><td class="xxxx-borders shading">95 (28.8)</td><td class="xxxx-borders shading">28 (24.3)</td><td class="xxxx-borders shading">66 (28.9)</td><td class="xxxr-borders shading">94 (27.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">NB-UVB phototherapy</td><td class="xxxx-borders">20 (18.3)</td><td class="xxxx-borders">41 (18.6)</td><td class="xxxx-borders">61 (18.5)</td><td class="xxxx-borders">27 (23.5)</td><td class="xxxx-borders">52 (22.8)</td><td class="xxxr-borders">79 (23.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Excimer laser therapy</td><td class="xxxx-borders shading">8 (7.3)</td><td class="xxxx-borders shading">18 (8.1)</td><td class="xxxx-borders shading">26 (7.9)</td><td class="xxxx-borders shading">14 (12.2)</td><td class="xxxx-borders shading">16 (7.0)</td><td class="xxxr-borders shading">30 (8.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">PUVA photochemotherapy</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">8 (3.6)</td><td class="xxxx-borders">12 (3.6)</td><td class="xxxx-borders">8 (7.0)</td><td class="xxxx-borders">15 (6.6)</td><td class="xxxr-borders">23 (6.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Vitamin D derivatives</td><td class="xxxx-borders shading">2 (1.8)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxx-borders shading">6 (1.8)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Other</td><td class="xbxx-borders">11 (10.1)</td><td class="xbxx-borders">24 (10.9)</td><td class="xbxx-borders">35 (10.6)</td><td class="xbxx-borders">14 (12.2)</td><td class="xbxx-borders">34 (14.9)</td><td class="xbxr-borders">48 (14.0)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Safety Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. BSA denotes body-surface area, NB-UVB narrow-band ultraviolet B, PUVA psoralen and ultraviolet A, TRuE-V1 Topical Ruxolitinib Evaluation in Vitiligo Study 1, and TRuE-V2 Topical Ruxolitinib Evaluation in Vitiligo Study 2.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race and ethnic group were reported by the patient. “Other” includes American Indian or Alaska Native, Native Hawaiian or Pacific Islander, and other.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Fitzpatrick skin types range from I to VI: type I indicates pale white; type II, white; type III, light brown; type IV, moderate brown; type V, dark brown; and type VI, deeply pigmented dark brown to black.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Scores on the facial Vitiligo Area Scoring Index (F-VASI) range from 0 to 3, with higher scores indicating a greater area of facial depigmentation.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Scores on the total Vitiligo Area Scoring Index (T-VASI) range from 0 to 100, with higher scores indicating a greater area of total body depigmentation.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">Shown is the percentage of total BSA.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">The determination of disease stability was based on investigator judgment.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t1fn8" role="paragraph">Patients could report multiple autoimmune disorders.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="t1fn9" role="paragraph">Patients could have used multiple previous lines of therapy. “Other” includes other types of phototherapy, oral glucocorticoids, surgical techniques, and other.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy</h3><section id="sec-2-2-1"><h4>Primary End Point: F-VASI75 Response at Week 24</h4><div role="paragraph"><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="two-c two-d">In TRuE-V1, approximately 66 of 221 patients (29.8%; missing values were estimated through multiple imputation for the primary end point) in the ruxolitinib-cream group and 8 of 109 patients (7.4%) in the vehicle group had an F-VASI75 response at week 24 (relative risk, 4.0; 95% confidence interval [CI], 1.9 to 8.4; P&lt;0.001). In TRuE-V2, approximately 69 of 222 patients (30.9%) in the ruxolitinib-cream group and 12 of 109 patients (11.4%) in the vehicle group had such a response (relative risk, 2.7; 95% CI, 1.5 to 4.9; P&lt;0.001) (<a href="#t2">Table 2</a> and Fig. S4A).</span> An F-VASI75 response was observed in 91 of 173 patients (52.6%) in TRuE-V1 and 85 of 177 patients (48.0%) in TRuE-V2 who applied ruxolitinib cream for 52 weeks and in 22 of 82 patients (27%) and 24 of 81 patients (30%), respectively, who crossed over from vehicle cream to ruxolitinib cream for 28 weeks.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t2.jpg"><img src="/cms/10.1056/NEJMoa2118828/asset/ba988464-0c88-4f7b-9cf1-f8ae3814495c/assets/images/large/nejmoa2118828_t2.jpg" height="1092" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders" colspan="4"><span>TRuE-V1</span></th><th class="txxr-borders" colspan="4"><span>TRuE-V2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Vehicle<br>(N=109)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=221)</th><th class="xxxx-borders">Relative Risk (95% CI)</th><th class="xxxx-borders">P Value</th><th class="xxxx-borders">Vehicle<br>(N=109)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=222)</th><th class="xxxx-borders">Relative Risk (95% CI)</th><th class="xxxr-borders">P Value</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">F-VASI75 response at wk 24 — % (95% CI)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">7.4 (2.2 to 12.6)</td><td class="xxxx-borders">29.8 (23.5 to 36.1)</td><td class="xxxx-borders">4.0 (1.9 to 8.4)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">11.4 (5.2 to 17.7)</td><td class="xxxx-borders">30.9 (24.5 to 37.3)</td><td class="xxxx-borders">2.7 (1.5 to 4.9)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Key secondary end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">F-VASI50 response at wk 24 — % (95% CI)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">16.9 (9.3 to 24.6)</td><td class="xxxx-borders">51.2 (44.4 to 58.0)</td><td class="xxxx-borders">3.0 (1.9 to 4.8)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">20.9 (12.9 to 28.9)</td><td class="xxxx-borders">51.4 (44.6 to 58.3)</td><td class="xxxx-borders">2.5 (1.6 to 3.7)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">F-VASI90 response at wk 24 — % (95% CI)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">2.2 (0 to 5.1)</td><td class="xxxx-borders shading">15.3 (10.4 to 20.2)</td><td class="xxxx-borders shading">7.3 (1.8 to 29.5)</td><td class="xxxx-borders shading">0.004</td><td class="xxxx-borders shading">1.3 (0 to 3.8)</td><td class="xxxx-borders shading">16.3 (11.2 to 21.5)</td><td class="xxxx-borders shading">13.1 (1.9 to 90.2)</td><td class="xxxr-borders shading">0.006</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">T-VASI50 response at wk 24 — % (95% CI)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">5.1 (0.6 to 9.7)</td><td class="xxxx-borders">20.6 (15.2 to 26.0)</td><td class="xxxx-borders">4.1 (1.6 to 10.5)</td><td class="xxxx-borders">0.002</td><td class="xxxx-borders">6.8 (1.9 to 11.7)</td><td class="xxxx-borders">23.9 (18.1 to 29.8)</td><td class="xxxx-borders">3.5 (1.7 to 7.5)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">VNS response at wk 24 — % (95% CI)<a href="#t2fn2" role="doc-noteref">†</a><a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">3.3 (0 to 6.9)</td><td class="xxxx-borders shading">24.5 (18.5 to 30.4)</td><td class="xxxx-borders shading">7.5 (2.4 to 23.5)</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">4.9 (0.7 to 9.2)</td><td class="xxxx-borders shading">20.5 (14.9 to 26.1)</td><td class="xxxx-borders shading">4.2 (1.7 to 10.2)</td><td class="xxxr-borders shading">0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">LSM percentage change from baseline in facial BSA affected by vitiligo at wk 24 (95% CI)<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xbxx-borders">–9.5 (–15.9 to –3.2)</td><td class="xbxx-borders">–28.9 (–33.2 to –24.5)</td><td class="xbxx-borders">NA</td><td class="xbxx-borders">&lt;0.001</td><td class="xbxx-borders">–7.0 (–14.5 to 0.5)</td><td class="xbxx-borders">–26.4 (–31.5 to –21.4)</td><td class="xbxx-borders">NA</td><td class="xbxr-borders">&lt;0.001</td></tr></tbody></table></div><figcaption><div class="caption">Primary and Key Secondary Efficacy End Points (Double-Blind Period; Modified Intention-to-Treat Population).<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">F-VASI50 denotes a decrease (improvement) of at least 50% in the F-VASI from baseline, F-VASI75 a decrease of at least 75% in the F-VASI from baseline, F-VASI90 a decrease of at least 90% in the F-VASI from baseline, NA not applicable, and T-VASI50 a decrease of at least 50% in the T-VASI from baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Multiple imputation was applied to account for missing values.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">A Vitiligo Noticeability Scale (VNS) response was defined as a rating of a lot less noticeable or no longer noticeable.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">An analysis of covariance model was applied to determine least-squares mean (LSM) and P value.</div></div></div></figcaption></figure></div></section><section id="sec-2-2-2"><h4>Key Secondary End Points</h4><div role="paragraph">At week 24, an F-VASI50 response was observed in approximately 113 of 221 patients (51.2%; missing values were estimated through multiple imputation for key secondary end points) in TRuE-V1 and 114 of 222 patients (51.4%) in TRuE-V2 who applied ruxolitinib cream, as compared with approximately 18 of 109 patients (16.9%) and 23 of 109 patients (20.9%), respectively, who applied vehicle cream (relative risk, 3.0 [95% CI, 1.9 to 4.8] and 2.5 [95% CI, 1.6 to 3.7], respectively; P&lt;0.001 in both trials) (<a href="#t2">Table 2</a> and Fig. S4B). An F-VASI90 response at week 24 occurred in approximately 34 of 221 patients (15.3%) in TRuE-V1 and 36 of 222 patients (16.3%) in TRuE-V2 with ruxolitinib cream, as compared with approximately 2 of 109 patients (2.2%) and 1 of 109 patients (1.3%), respectively, with vehicle (relative risk, 7.3 [95% CI, 1.8 to 29.5] [P=0.004] and 13.1 [95% CI, 1.9 to 90.2] [P=0.006], respectively) (<a href="#t2">Table 2</a> and Fig. S4C). F-VASI50 and F-VASI90 responses were numerically greater at week 52 than at week 24 (Table S2). A T-VASI50 response at week 24 was observed in approximately 46 of 221 patients (20.6%) in TRuE-V1 and 53 of 222 patients (23.9%) in TRuE-V2 who applied ruxolitinib cream, as compared with approximately 6 of 109 patients (5.1%) and 7 of 109 patients (6.8%), respectively, who applied vehicle cream (relative risk, 4.1 [95% CI, 1.6 to 10.5] [P=0.002] and 3.5 [95% CI, 1.7 to 7.5] [P&lt;0.001], respectively) (<a href="#t2">Table 2</a> and Fig. S4D). A T-VASI50 response occurred in 92 of 173 patients (53.2%) in TRuE-V1 and 87 of 177 patients (49.2%) in TRuE-V2 who applied ruxolitinib cream for 52 weeks and in 26 of 82 patients (32%) and 18 of 81 patients (22%), respectively, who crossed over from vehicle cream to ruxolitinib cream for 28 weeks. A VNS response at week 24 occurred in approximately 54 of 221 patients (24.5%) in TRuE-V1 and 46 of 222 patients (20.5%) in TRuE-V2 with ruxolitinib cream, as compared with approximately 4 of 109 patients (3.3%) and 5 of 109 patients (4.9%), respectively, with vehicle (relative risk, 7.5 [95% CI, 2.4 to 23.5] [P&lt;0.001] and 4.2 [95% CI, 1.7 to 10.2] [P=0.001], respectively) (<a href="#t2">Table 2</a> and Figs. S5A and S6); a numerically greater percentage of patients had VNS responses at week 52 than at week 24. The least-squares mean percentage change from baseline in facial body-surface area affected by vitiligo was –28.9% in TRuE-V1 and –26.4% in TRuE-V2 with ruxolitinib cream, as compared with –9.5% and –7.0%, respectively, with vehicle (P&lt;0.001 in both trials) (<a href="#t2">Table 2</a> and Fig. S5B).</div></section><section id="sec-2-2-3"><h4>Other Secondary and Exploratory End Points</h4><div role="paragraph">Patients who applied ruxolitinib cream rather than vehicle cream had numerically greater improvements from baseline, with separation between trial groups at approximately week 12 in the F-VASI and T-VASI on the basis of visual inspection of values over time (Fig. S7) as well as facial body-surface area and total body-surface area affected by vitiligo (Fig. S8), with continued separation through week 52 on the basis of visual inspection; however, no definite conclusions can be drawn from these data because there was no adjustment of the widths of confidence intervals for multiple comparisons. Patients who applied ruxolitinib cream showed visible improvement in repigmentation of facial and nonfacial lesions (Fig. S9). However, there were no meaningful improvements from baseline in DLQI and CDLQI scores through week 52. Data on these end points are also provided in Table S2.</div><div role="paragraph">At week 24, a numerically larger percentage of patients who applied ruxolitinib cream rather than vehicle cream had F-PhGVA and T-PhGVA responses (Fig. S10) as well as F-PaGIC-V and T-PaGIC-V responses (Fig. S11), with further improvement at week 52 on the basis of visual inspection of results over time; however, no conclusions can be drawn from these data because there was no adjustment for multiplicity. The percentage of patients who reported good-to-excellent color-matching was higher in the ruxolitinib-cream group than in the vehicle group at week 24 (Fig. S12).</div></section></section><section id="sec-2-3"><h3>Safety and Pharmacokinetics</h3><div role="paragraph"><a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">The incidences and types of adverse events that emerged or worsened after the first dose of a trial agent were similar in both trials (<a href="#t3">Table 3</a>). In the double-blind period, adverse events were mainly mild or moderate and occurred in 45.7% (TRuE-V1) and 50.0% (TRuE-V2) of the patients in the ruxolitinib-cream group and in 38.5% and 33.9%, respectively, of the patients in the vehicle group. The most common adverse events were application-site acne (ruxolitinib-cream group, 5.9% in TRuE-V1 and 5.7% in TRuE-V2; vehicle group, none and 2.6%, respectively) and application-site pruritus (ruxolitinib-cream group, 5.0% in TRuE-V1 and 5.3% in TRuE-V2; vehicle group, 3.7% and 1.7%, respectively). All acne and pruritus events were mild or moderate; patients continued treatment with ruxolitinib cream, with the exception of one patient with acne who had a 3-day dose change to once-daily application before resuming twice-daily application. Safety findings were generally consistent in the open-label treatment extension (<a href="#t3">Table 3</a>).</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t3.jpg"><img src="/cms/10.1056/NEJMoa2118828/asset/d7369af1-2173-439d-aefb-f6acf9615744/assets/images/large/nejmoa2118828_t3.jpg" height="2765" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="4"><span>TRuE-V1</span></th><th class="txxr-borders" colspan="4"><span>TRuE-V2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>Double-Blind Period<a href="#t3fn1" role="doc-noteref">*</a></span></th><th class="xxxx-borders" colspan="2"><span>Extension Period<a href="#t3fn2" role="doc-noteref">†</a></span></th><th class="xxxx-borders" colspan="2"><span>Double-Blind Period<a href="#t3fn1" role="doc-noteref">*</a></span></th><th class="xxxr-borders" colspan="2"><span>Extension Period<a href="#t3fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Vehicle<br>(N=109)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=221)</th><th class="xxxx-borders">Vehicle to 1.5% Ruxolitinib Cream<br>(N=90)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=193)</th><th class="xxxx-borders">Vehicle<br>(N=115)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=228)</th><th class="xxxx-borders">Vehicle to 1.5% Ruxolitinib Cream<br>(N=98)</th><th class="xxxr-borders">1.5% Ruxolitinib Cream<br>(N=199)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="8"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">42 (38.5)</td><td class="xxxx-borders shading">101 (45.7)</td><td class="xxxx-borders shading">31 (34.4)</td><td class="xxxx-borders shading">65 (33.7)</td><td class="xxxx-borders shading">39 (33.9)</td><td class="xxxx-borders shading">114 (50.0)</td><td class="xxxx-borders shading">38 (38.8)</td><td class="xxxr-borders shading">82 (41.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Most common adverse events<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Covid-19<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">5 (4.6)</td><td class="xxxx-borders shading">3 (1.4)</td><td class="xxxx-borders shading">1 (1.1)</td><td class="xxxx-borders shading">11 (5.7)</td><td class="xxxx-borders shading">2 (1.7)</td><td class="xxxx-borders shading">10 (4.4)</td><td class="xxxx-borders shading">5 (5.1)</td><td class="xxxr-borders shading">9 (4.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Application-site acne</td><td class="xxxx-borders">0</td><td class="xxxx-borders">13 (5.9)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.5)</td><td class="xxxx-borders">3 (2.6)</td><td class="xxxx-borders">13 (5.7)</td><td class="xxxx-borders">5 (5.1)</td><td class="xxxr-borders">3 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">9 (4.1)</td><td class="xxxx-borders shading">2 (2.2)</td><td class="xxxx-borders shading">3 (1.6)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">10 (4.4)</td><td class="xxxx-borders shading">3 (3.1)</td><td class="xxxr-borders shading">4 (2.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Headache</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxx-borders">6 (2.7)</td><td class="xxxx-borders">2 (2.2)</td><td class="xxxx-borders">3 (1.6)</td><td class="xxxx-borders">4 (3.5)</td><td class="xxxx-borders">11 (4.8)</td><td class="xxxx-borders">1 (1.0)</td><td class="xxxr-borders">6 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Application-site pruritus</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">11 (5.0)</td><td class="xxxx-borders shading">1 (1.1)</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">2 (1.7)</td><td class="xxxx-borders shading">12 (5.3)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders">5 (4.6)</td><td class="xxxx-borders">6 (2.7)</td><td class="xxxx-borders">3 (3.3)</td><td class="xxxx-borders">2 (1.0)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (3.1)</td><td class="xxxx-borders">2 (2.0)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Sinusitis</td><td class="xxxx-borders shading">3 (2.8)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxx-borders shading">1 (1.1)</td><td class="xxxx-borders shading">3 (1.6)</td><td class="xxxx-borders shading">2 (1.7)</td><td class="xxxx-borders shading">6 (2.6)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Application-site dermatitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">5 (2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Application-site rash</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">5 (2.3)</td><td class="xxxx-borders hanging11 shading">1 (1.1)</td><td class="xxxx-borders hanging11 shading">1 (0.5)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Oral herpes</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders hanging11">2 (2.2)</td><td class="xxxx-borders hanging11">2 (1.0)</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">3 (1.3)</td><td class="xxxx-borders">1 (1.0)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Urinary tract infection</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">5 (2.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxx-borders shading">1 (1.0)</td><td class="xxxr-borders shading">2 (1.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Acne</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">3 (3.3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxx-borders">1 (1.0)</td><td class="xxxr-borders">2 (1.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pyrexia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (2.2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Application-site exfoliation</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">5 (2.2)</td><td class="xxxx-borders">1 (1.0)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hypothyroidism</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (2.2)</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event related to trial agent<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">10 (9.2)</td><td class="xxxx-borders">38 (17.2)</td><td class="xxxx-borders">5 (5.6)</td><td class="xxxx-borders">7 (3.6)</td><td class="xxxx-borders">6 (5.2)</td><td class="xxxx-borders">28 (12.3)</td><td class="xxxx-borders">6 (6.1)</td><td class="xxxr-borders">12 (6.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Most common adverse events related to trial agent<a href="#t3fn3" role="doc-noteref">‡</a><a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Application-site acne</td><td class="xxxx-borders">0</td><td class="xxxx-borders">12 (5.4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.5)</td><td class="xxxx-borders">2 (1.7)</td><td class="xxxx-borders">10 (4.4)</td><td class="xxxx-borders">3 (3.1)</td><td class="xxxr-borders">3 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Application-site pruritus</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">11 (5.0)</td><td class="xxxx-borders shading">1 (1.1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1.7)</td><td class="xxxx-borders shading">10 (4.4)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Application-site exfoliation</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">5 (2.2)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event<a href="#t3fn6" role="doc-noteref">‖</a><a href="#t3fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">6 (2.7)</td><td class="xxxx-borders shading">1 (1.1)</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">2 (2.0)</td><td class="xxxr-borders shading">2 (1.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Adverse event leading to discontinuation of trial agent</td><td class="xbxx-borders">1 (0.9)</td><td class="xbxx-borders">1 (0.5)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (0.4)</td><td class="xbxx-borders">0</td><td class="xbxr-borders">1 (0.5)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events during the Double-Blind Period and Open-Label Treatment Extension Period.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Adverse events during the double-blind period (up to week 24) are reported in the safety population (ruxolitinib-cream group and vehicle group).</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Adverse events during the open-label treatment extension period (after week 24) are reported in the treatment-extension evaluable population (ruxolitinib-cream group and vehicle-to-ruxolitinib-cream group).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">Shown are events that occurred in more than 2% of the patients in any group.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">On the basis of the prevalence of coronavirus disease 2019 (Covid-19) at the time the trials were conducted, the incidence of Covid-19 was not considered to be relevant to ruxolitinib-cream application.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">The relatedness of the adverse event to the trial agent was determined by the investigator.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t3fn6" role="paragraph">No serious adverse events were considered by investigators to be related to the trial agent according to criteria prespecified in the protocol.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t3fn7" role="paragraph">In TRuE-V1, serious adverse events with application of ruxolitinib cream were anal fistula, appendicitis, concussion, hepatitis due to infectious mononucleosis, hypersensitivity, kidney contusion, myocarditis, prostate cancer, and subacute combined cord degeneration (in one patient each); hypersensitivity and subacute combined cord degeneration occurred in the same patient. In TRuE-V2, serious adverse events with ruxolitinib cream were appendiceal abscess, coronary-artery stenosis, joint dislocation, papillary thyroid cancer, rhabdomyolysis, and ureterolithiasis (in one patient each).</div></div></div></figcaption></figure></div><div role="paragraph">Among patients who applied ruxolitinib cream throughout 52 weeks, adverse events occurred in 54.8% of the patients in TRuE-V1 and in 62.3% of those in TRuE-V2. The most common adverse events (other than coronavirus disease 2019 [Covid-19], which, on the basis of its prevalence at the time the trials were conducted, was not considered to be relevant to ruxolitinib-cream application) were application-site acne (6.3% in TRuE-V1 and 6.6% in TRuE-V2), nasopharyngitis (5.4% and 6.1%, respectively), and application-site pruritus (5.4% and 5.3%) (Table S3). It is notable that only 5 patients who applied ruxolitinib cream at any time during the 52-week trials reported application-site pain that was considered to be related to treatment. A total of 14 patients who applied ruxolitinib cream at any time during the trials had serious adverse events (Table S4). Three patients discontinued double-blind treatment because of an adverse event (fatigue and application-site rash in 1 patient each in the ruxolitinib-cream group and nausea and headache in the same patient in the vehicle group), and 1 patient discontinued the open-label treatment extension (application-site eczema in 1 patient).</div><div role="paragraph">The incidence of hematopoietic adverse events was less than 1% (Table S5); such events were mild or moderate in severity, and none were considered to be related to the trial agent. The majority of patients had normal hemoglobin and platelet levels throughout the treatment period (Fig. S13). Plasma concentrations of ruxolitinib were similar in the two trials (mean [±SD] steady-state concentration average of weeks 4 and 24, 55.8±56.7 nM in TRuE-V1 and 58.0±68.1 nM in TRuE-V2) (Fig. S14 and Table S6).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b">These two phase 3, double-blind, randomized, vehicle-controlled trials of repigmentation therapy in patients with vitiligo yielded similar results, showing statistical superiority of 1.5% ruxolitinib cream twice daily over vehicle cream for the primary and all key secondary end points at week 24, with approximately one third of patients having an F-VASI75 response for facial repigmentation (primary end point).</span> The results for secondary end points were generally in the same direction as the results of the primary analysis. There was a numerical increase in the percentage of patients who met the criteria for the primary and key secondary end points through week 52, including among patients who crossed over from vehicle to ruxolitinib cream for 28 weeks; however, no definite conclusions can be drawn from these results because of the lack of multiplicity correction. Efficacy at week 52 in patients who crossed over to active treatment, after 28 weeks of ruxolitinib cream, was consistent with week 24 data in patients who applied ruxolitinib cream from day 1.</div><div role="paragraph">These trials examined facial repigmentation as the primary end point and total body repigmentation as one of five key secondary end points. The repigmentation process is lengthy.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup> JAK inhibition with ruxolitinib cream reduces skin-associated inflammatory mediators (e.g., CXCL10) in circulation,<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-3" href-manipulated="true" aria-label="Reference 17">17</a></sup> disrupting vitiligo pathogenesis and allowing time for melanocyte recruitment and repigmentation.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> The lower incidence of total body repigmentation than of facial repigmentation after 6 months of treatment, with approximately 20% of patients having a T-VASI50 response and 50% of patients having an F-VASI50 response, is due to recognized differences in the nature of repigmentation of facial as compared with nonfacial body areas. The rate of nonfacial repigmentation is further affected by involvement of the hands and feet, which are typically resistant to repigmentation, partly because of a lower density of hair follicles.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup></div><div role="paragraph">Phase 2 trial data with ruxolitinib cream showed that F-VASI75 and T-VASI50 responses indicate clinically meaningful repigmentation.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-4" href-manipulated="true" aria-label="Reference 17">17</a></sup> These findings were supported by another study that showed that most patients considered at least 75% facial repigmentation and at least 50% nonfacial repigmentation to be indicators of treatment success.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> In TRuE-V1 and TRuE-V2, half the patients who applied ruxolitinib cream from day 1 had at least 75% facial repigmentation and at least 50% total body repigmentation at 1 year. No direct comparisons can be made with existing data for repigmentation with other monotherapies,<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25 r26" id="body-ref-r26" href-manipulated="true">25,26</a></sup> including phototherapy,<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27 r28" id="body-ref-r28" href-manipulated="true">27,28</a></sup> or with combination therapy.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r29 r30 r31" id="body-ref-r31" href-manipulated="true">15,29–31</a></sup> A clinical trial investigating ruxolitinib cream in combination with narrow-band ultraviolet B phototherapy in patients with vitiligo is in progress (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT05247489" target="_blank">NCT05247489</a>).</div><div role="paragraph">The efficacy of ruxolitinib cream was supported by positive patient-reported outcomes, including rating vitiligo lesions as a lot less or no longer noticeable (VNS response), rating lesions as much or very much improved (PaGIC-V response), and reporting color-matching as good to excellent during 24 weeks of double-blind treatment. Although not comparable, a higher percentage of patients than of physicians reported a favorable response to treatment according to the PaGIC-V and the PhGVA, respectively, which indicates that patients may be more optimistic regarding changes in their lesions. Nonetheless, no meaningful quality-of-life improvements were evident in the two trials; however, the DLQI and CDLQI instruments include physical symptoms such as itch and pain<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r19" id="body-ref-r19-2" href-manipulated="true">18,19</a></sup> and may lack sensitivity in vitiligo.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32" href-manipulated="true" aria-label="Reference 32">32</a></sup></div><div role="paragraph">The incidences of adverse events with ruxolitinib cream were similar across both trials. Application-site acne and application-site pruritus were the most common treatment-related adverse events, each reported in approximately 5% of the patients who applied ruxolitinib cream for 52 weeks; there were no resulting treatment discontinuations. Acne is a common adverse event with JAK inhibitors,<sup><a href="#core-r33" role="doc-biblioref" data-xml-rid="r33" id="body-ref-r33" href-manipulated="true" aria-label="Reference 33">33</a></sup> although the pathogenesis of acne in this context is not yet understood. Further analyses to better understand and characterize these acneiform lesions are warranted. It is notable that stinging or burning at the application site, which is often reported with topical calcineurin inhibitors,<sup><a href="#core-r34" role="doc-biblioref" data-xml-rid="r34" id="body-ref-r34" href-manipulated="true" aria-label="Reference 34">34</a></sup> was infrequent with ruxolitinib cream. In addition, mean plasma concentrations of ruxolitinib were well below the half-maximal concentration for thrombopoietin-stimulated STAT3 phosphorylation (281 nM),<sup><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35" id="body-ref-r35" href-manipulated="true" aria-label="Reference 35">35</a></sup> a proxy for evaluating JAK-related myelosuppression in bone marrow. Hematopoietic adverse events were infrequent and were considered by the investigators to be unrelated to treatment.</div><div role="paragraph">Limitations to interpreting these trial results include that the trials were conducted during the Covid-19 pandemic, which may have contributed to patients being lost to follow-up. In addition, most enrolled patients were White and had skin types I, II, or III. Although generalization to patients with darker skin types is limited on the basis of patient enrollment, subgroup analyses of phase 2 data indicated that incidences of repigmentation response may be similar among patients with fairer skin and those with darker skin<sup><a href="#core-r36" role="doc-biblioref" data-xml-rid="r36" id="body-ref-r36" href-manipulated="true" aria-label="Reference 36">36</a></sup>; similar analysis of pooled phase 3 data from TRuE-V1 and TRuE-V2 is ongoing. Because skin pigmentation (coloring) is dependent on melanin production by melanocytes and is regulated by genetic and environmental factors, among others,<sup><a href="#core-r37" role="doc-biblioref" data-xml-rid="r37" id="body-ref-r37" href-manipulated="true" aria-label="Reference 37">37</a></sup> restoring melanocyte function (through JAK inhibition) may be sufficient to restore consistent skin coloring regardless of skin type. Long-term safety evaluations of ruxolitinib cream from the 156-week phase 2 trial are ongoing.</div><div role="paragraph">In these two phase 3 trials, ruxolitinib cream showed superiority to vehicle control in repigmentation of vitiligo. Patient-reported outcomes suggest that changes were meaningful to patients, although there were no substantial between-group differences in quality of life. Larger and longer trials are required to determine the effect and risks of ruxolitinib cream for the treatment of vitiligo.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Incyte</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients, families, and caregivers who participated in the trials; the staff at each trial site; Jim Lee, M.D., Ph.D., and Ahmad Naim, M.D. (Incyte), for their critical review of the manuscript; and Wendy van der Spuy, Ph.D., an employee of ICON (Blue Bell), for writing assistance with an earlier version of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2118828_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2118828/suppl_file/nejmoa2118828_research-summary.pdf" download="nejmoa2118828_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2118828_research-summary.pdf" data-doi="10.1056/NEJMoa2118828">Download</a></li><li>403.68 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2118828_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2118828/suppl_file/nejmoa2118828_protocol.pdf" download="nejmoa2118828_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2118828_protocol.pdf" data-doi="10.1056/NEJMoa2118828">Download</a></li><li>3.72 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2118828_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2118828/suppl_file/nejmoa2118828_appendix.pdf" download="nejmoa2118828_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2118828_appendix.pdf" data-doi="10.1056/NEJMoa2118828">Download</a></li><li>2.02 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2118828_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2118828/suppl_file/nejmoa2118828_disclosures.pdf" download="nejmoa2118828_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2118828_disclosures.pdf" data-doi="10.1056/NEJMoa2118828">Download</a></li><li>888.45 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2118828_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2118828/suppl_file/nejmoa2118828_data-sharing.pdf" download="nejmoa2118828_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2118828_data-sharing.pdf" data-doi="10.1056/NEJMoa2118828">Download</a></li><li>72.95 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. <em>J Am Acad Dermatol</em> 2017;77:1-13.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2016.10.048" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28619550/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403205000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+discoveries+in+the+pathogenesis+and+classification+of+vitiligo.&amp;publication_year=2017&amp;journal=J+Am+Acad+Dermatol&amp;pages=1-13&amp;doi=10.1016%2Fj.jaad.2016.10.048&amp;pmid=28619550" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] disease that results in skin depigmentation </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] functioning melanocytes in the epidermis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Boniface K, Seneschal J, Picardo M, Taïeb A. Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. <em>Clin Rev Allergy Immunol</em> 2018;54:52-67.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12016-017-8622-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28685247/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000424247300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vitiligo%3A+focus+on+clinical+aspects%2C+immunopathogenesis%2C+and+therapy.&amp;publication_year=2018&amp;journal=Clin+Rev+Allergy+Immunol&amp;pages=52-67&amp;doi=10.1007%2Fs12016-017-8622-7&amp;pmid=28685247" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] disease that results in skin depigmentation </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] functioning melanocytes in the epidermis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Morrison B, Burden-Teh E, Batchelor JM, Mead E, Grindlay D, Ratib S. Quality of life in people with vitiligo: a systematic review and meta-analysis. <em>Br J Dermatol</em> 2017;177(6):e338-e339.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjd.15933" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28869779/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000419479300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Quality+of+life+in+people+with+vitiligo%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2017&amp;journal=Br+J+Dermatol&amp;pages=e338-e339&amp;doi=10.1111%2Fbjd.15933&amp;pmid=28869779" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. <em>Am J Clin Dermatol</em> 2021;22:757-774.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40257-021-00631-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34554406/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000698537000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Psychosocial+effects+of+vitiligo%3A+a+systematic+literature+review.&amp;publication_year=2021&amp;journal=Am+J+Clin+Dermatol&amp;pages=757-774&amp;doi=10.1007%2Fs40257-021-00631-6&amp;pmid=34554406" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and reduced quality of life. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and extensive body-area involvement. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Rashighi M, Harris JE. Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. <em>Ann Transl Med</em> 2015;3:343-343.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26734651/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interfering+with+the+IFN-%CE%B3%2FCXCL10+pathway+to+develop+new+targeted+treatments+for+vitiligo.&amp;publication_year=2015&amp;journal=Ann+Transl+Med&amp;pages=343-343&amp;pmid=26734651" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] activator of transcription (STAT) pathway, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which drives melanocyte destruction. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Martins C, Migayron L, Drullion C, et al. Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling. <em>J Invest Dermatol</em> 2022;142(4):1194-1205.e7.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jid.2021.09.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34655610/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000771485000032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vitiligo+skin+T+cells+are+prone+to+produce+type+1+and+type+2+cytokines+to+induce+melanocyte+dysfunction+and+epidermal+inflammatory+response+through+Jak+signaling.&amp;publication_year=2022&amp;journal=J+Invest+Dermatol&amp;pages=1194-1205.e7&amp;doi=10.1016%2Fj.jid.2021.09.015&amp;pmid=34655610" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] activator of transcription (STAT) pathway, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which drives melanocyte destruction. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. <em>J Invest Dermatol</em> 2009;129:2220-2232.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/jid.2009.32" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19242513/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000268939700021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Autoimmune+destruction+of+skin+melanocytes+by+perilesional+T+cells+from+vitiligo+patients.&amp;publication_year=2009&amp;journal=J+Invest+Dermatol&amp;pages=2220-2232&amp;doi=10.1038%2Fjid.2009.32&amp;pmid=19242513" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Chen J, Li S, Li C. Mechanisms of melanocyte death in vitiligo. <em>Med Res Rev</em> 2021;41:1138-1166.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/med.21754" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33200838/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000589752800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mechanisms+of+melanocyte+death+in+vitiligo.&amp;publication_year=2021&amp;journal=Med+Res+Rev&amp;pages=1138-1166&amp;doi=10.1002%2Fmed.21754&amp;pmid=33200838" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Wang XX, Wang QQ, Wu JQ, et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. <em>Br J Dermatol</em> 2016;174:1318-1326.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjd.14416" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26801009/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000378047100028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+expression+of+CXCR3+and+its+ligands+in+patients+with+vitiligo+and+CXCL10+as+a+potential+clinical+marker+for+vitiligo.&amp;publication_year=2016&amp;journal=Br+J+Dermatol&amp;pages=1318-1326&amp;doi=10.1111%2Fbjd.14416&amp;pmid=26801009" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Ferrari SM, Fallahi P, Santaguida G, et al. Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis. <em>Autoimmun Rev</em> 2017;16:946-950.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.autrev.2017.07.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28698095/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410869200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Circulating+CXCL10+is+increased+in+non-segmental+vitiligo%2C+in+presence+or+absence+of+autoimmune+thyroiditis.&amp;publication_year=2017&amp;journal=Autoimmun+Rev&amp;pages=946-950&amp;doi=10.1016%2Fj.autrev.2017.07.006&amp;pmid=28698095" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8<sup>+</sup> T-cell accumulation in the skin. <em>J Invest Dermatol</em> 2012;132:1869-1876.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/jid.2011.463" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22297636/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000305492900019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+mouse+model+of+vitiligo+with+focused+epidermal+depigmentation+requires+IFN-%CE%B3+for+autoreactive+CD8%2B+T-cell+accumulation+in+the+skin.&amp;publication_year=2012&amp;journal=J+Invest+Dermatol&amp;pages=1869-1876&amp;doi=10.1038%2Fjid.2011.463&amp;pmid=22297636" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Regazzetti C, Joly F, Marty C, et al. Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients. <em>J Invest Dermatol</em> 2015;135:3105-3114.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/jid.2015.335" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26322948/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365181100030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Transcriptional+analysis+of+vitiligo+skin+reveals+the+alteration+of+WNT+pathway%3A+a+promising+target+for+repigmenting+vitiligo+patients.&amp;publication_year=2015&amp;journal=J+Invest+Dermatol&amp;pages=3105-3114&amp;doi=10.1038%2Fjid.2015.335&amp;pmid=26322948" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Bergqvist C, Ezzedine K. Vitiligo: a focus on pathogenesis and its therapeutic implications. <em>J Dermatol</em> 2021;48:252-270.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/1346-8138.15743" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33404102/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605018200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vitiligo%3A+a+focus+on+pathogenesis+and+its+therapeutic+implications.&amp;publication_year=2021&amp;journal=J+Dermatol&amp;pages=252-270&amp;doi=10.1111%2F1346-8138.15743&amp;pmid=33404102" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. <em>J Am Acad Dermatol</em> 2017;76(6):1054-1060.e1.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2017.02.049" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28390737/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000402797000024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+vitiligo+with+the+topical+Janus+kinase+inhibitor+ruxolitinib.&amp;publication_year=2017&amp;journal=J+Am+Acad+Dermatol&amp;pages=1054-1060.e1&amp;doi=10.1016%2Fj.jaad.2017.02.049&amp;pmid=28390737" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. <em>J Am Acad Dermatol</em> 2017;77(4):675-682.e1.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2017.05.043" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28823882/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410627400022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Repigmentation+in+vitiligo+using+the+Janus+kinase+inhibitor+tofacitinib+may+require+concomitant+light+exposure.&amp;publication_year=2017&amp;journal=J+Am+Acad+Dermatol&amp;pages=675-682.e1&amp;doi=10.1016%2Fj.jaad.2017.05.043&amp;pmid=28823882" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] after treatment with JAK inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r31" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] or with combination therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Joshipura D, Alomran A, Zancanaro P, Rosmarin D. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. <em>J Am Acad Dermatol</em> 2018;78(6):1205-1207.e1.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2018.02.023" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29438765/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000432494000033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+vitiligo+with+the+topical+Janus+kinase+inhibitor+ruxolitinib%3A+a+32-week+open-label+extension+study+with+optional+narrow-band+ultraviolet+B.&amp;publication_year=2018&amp;journal=J+Am+Acad+Dermatol&amp;pages=1205-1207.e1&amp;doi=10.1016%2Fj.jaad.2018.02.023&amp;pmid=29438765" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. <em>Lancet</em> 2020;396:110-120.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)30609-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32653055/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000552724600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ruxolitinib+cream+for+treatment+of+vitiligo%3A+a+randomised%2C+controlled%2C+phase+2+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=110-120&amp;doi=10.1016%2FS0140-6736%2820%2930609-7&amp;pmid=32653055" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] trial involving adults with vitiligo. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] 75%, with improvement through week 52. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] mediators (e.g., CXCL10) in circulation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] clinically meaningful repigmentation. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use. <em>Clin Exp Dermatol</em> 1994;19:210-216.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2230.1994.tb01167.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8033378/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994NN18000003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dermatology+Life+Quality+Index+%28DLQI%29+%E2%80%94+a+simple+practical+measure+for+routine+clinical+use.&amp;publication_year=1994&amp;journal=Clin+Exp+Dermatol&amp;pages=210-216&amp;doi=10.1111%2Fj.1365-2230.1994.tb01167.x&amp;pmid=8033378" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Life Quality Index (DLQI [for adults]) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] physical symptoms such as itch and pain </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. <em>Br J Dermatol</em> 1995;132:942-949.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2133.1995.tb16953.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7662573/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1995RC52200015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+Children%E2%80%99s+Dermatology+Life+Quality+Index+%28CDLQI%29%3A+initial+validation+and+practical+use.&amp;publication_year=1995&amp;journal=Br+J+Dermatol&amp;pages=942-949&amp;doi=10.1111%2Fj.1365-2133.1995.tb16953.x&amp;pmid=7662573" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Dermatology Life Quality Index (CDLQI) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] physical symptoms such as itch and pain </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken, NJ: John Wiley, 1987.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Rubin+DB.+Multiple+imputation+for+nonresponse+in+surveys.+Hoboken%2C+NJ%3A+John+Wiley%2C+1987." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Gan EY, Eleftheriadou V, Esmat S, et al. Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference. <em>Pigment Cell Melanoma Res</em> 2017;30:28-40.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/pcmr.12561" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27864868/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393957200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Repigmentation+in+vitiligo%3A+position+paper+of+the+Vitiligo+Global+Issues+Consensus+Conference.&amp;publication_year=2017&amp;journal=Pigment+Cell+Melanoma+Res&amp;pages=28-40&amp;doi=10.1111%2Fpcmr.12561&amp;pmid=27864868" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Joshipura D, Plotnikova N, Goldminz A, et al. Importance of light in the treatment of vitiligo with JAK-inhibitors. <em>J Dermatolog Treat</em> 2018;29:98-99.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/09546634.2017.1339013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28581823/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423855400017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Importance+of+light+in+the+treatment+of+vitiligo+with+JAK-inhibitors.&amp;publication_year=2018&amp;journal=J+Dermatolog+Treat&amp;pages=98-99&amp;doi=10.1080%2F09546634.2017.1339013&amp;pmid=28581823" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Esmat SM, El-Tawdy AM, Hafez GA, et al. Acral lesions of vitiligo: why are they resistant to photochemotherapy? <em>J Eur Acad Dermatol Venereol</em> 2012;26:1097-1104.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1468-3083.2011.04215.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21851425/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000307555400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Acral+lesions+of+vitiligo%3A+why+are+they+resistant+to+photochemotherapy%3F&amp;publication_year=2012&amp;journal=J+Eur+Acad+Dermatol+Venereol&amp;pages=1097-1104&amp;doi=10.1111%2Fj.1468-3083.2011.04215.x&amp;pmid=21851425" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Narayan VS, Uitentuis SE, Bekkenk MW, Wolkerstorfer A. What is successful repigmentation in vitiligo from the point of view of patients? <em>Br J Dermatol</em> 2021;184:165-166.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjd.19422" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32726875/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000568590200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=What+is+successful+repigmentation+in+vitiligo+from+the+point+of+view+of+patients%3F&amp;publication_year=2021&amp;journal=Br+J+Dermatol&amp;pages=165-166&amp;doi=10.1111%2Fbjd.19422&amp;pmid=32726875" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Sanclemente G, Garcia JJ, Zuleta JJ, Diehl C, Correa C, Falabella R. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. <em>J Eur Acad Dermatol Venereol</em> 2008;22:1359-1364.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1468-3083.2008.02839.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18624857/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000259959900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+double-blind%2C+randomized+trial+of+0.05%25+betamethasone+vs.+topical+catalase%2Fdismutase+superoxide+in+vitiligo.&amp;publication_year=2008&amp;journal=J+Eur+Acad+Dermatol+Venereol&amp;pages=1359-1364&amp;doi=10.1111%2Fj.1468-3083.2008.02839.x&amp;pmid=18624857" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Chang H-C, Hsu Y-P, Huang Y-C. The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis. <em>J Am Acad Dermatol</em> 2020;82:243-245.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2019.07.108" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31408687/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000502846000050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+effectiveness+of+topical+calcineurin+inhibitors+compared+with+topical+corticosteroids+in+the+treatment+of+vitiligo%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2020&amp;journal=J+Am+Acad+Dermatol&amp;pages=243-245&amp;doi=10.1016%2Fj.jaad.2019.07.108&amp;pmid=31408687" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Bae JM, Jung HM, Hong BY, et al. Phototherapy for vitiligo: a systematic review and meta-analysis. <em>JAMA Dermatol</em> 2017;153:666-674.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamadermatol.2017.0002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28355423/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405476000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phototherapy+for+vitiligo%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2017&amp;journal=JAMA+Dermatol&amp;pages=666-674&amp;doi=10.1001%2Fjamadermatol.2017.0002&amp;pmid=28355423" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. <em>Arch Dermatol</em> 2007;143:578-584.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/archderm.143.5.578" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17519217/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000246477300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+double-blind+trial+of+treatment+of+vitiligo%3A+efficacy+of+psoralen-UV-A+therapy+vs+narrowband-UV-B+therapy.&amp;publication_year=2007&amp;journal=Arch+Dermatol&amp;pages=578-584&amp;doi=10.1001%2Farchderm.143.5.578&amp;pmid=17519217" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Yoshida A, Takagi A, Ikejima A, Takenaka H, Fukai T, Ikeda S. A retrospective study of 231 Japanese vitiligo patients with special reference to phototherapy. <em>Acta Dermatovenerol Croat</em> 2014;22:13-18.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24813836/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000336639800002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+retrospective+study+of+231+Japanese+vitiligo+patients+with+special+reference+to+phototherapy.&amp;publication_year=2014&amp;journal=Acta+Dermatovenerol+Croat&amp;pages=13-18&amp;pmid=24813836" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Khemis A, Fontas E, Moulin S, Montaudié H, Lacour JP, Passeron T. Apremilast in combination with narrowband UVB in the treatment of vitiligo: a 52-week monocentric prospective randomized placebo-controlled study. <em>J Invest Dermatol</em> 2020;140(8):1533-1537.e2.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jid.2019.11.031" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32004567/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000551035500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Apremilast+in+combination+with+narrowband+UVB+in+the+treatment+of+vitiligo%3A+a+52-week+monocentric+prospective+randomized+placebo-controlled+study.&amp;publication_year=2020&amp;journal=J+Invest+Dermatol&amp;pages=1533-1537.e2&amp;doi=10.1016%2Fj.jid.2019.11.031&amp;pmid=32004567" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Fontas E, Montaudié H, Passeron T. Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: a 24-week prospective randomized placebo-controlled study. <em>J Eur Acad Dermatol Venereol</em> 2021;35:1725-1729.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/jdv.17331" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33931900/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000649840100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oral+gliadin-protected+superoxide+dismutase+in+addition+to+phototherapy+for+treating+non-segmental+vitiligo%3A+a+24-week+prospective+randomized+placebo-controlled+study.&amp;publication_year=2021&amp;journal=J+Eur+Acad+Dermatol+Venereol&amp;pages=1725-1729&amp;doi=10.1111%2Fjdv.17331&amp;pmid=33931900" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. <em>J Eur Acad Dermatol Venereol</em> 2022;36:1507-1523.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/jdv.18129" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35366355/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000793254200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+humanistic+burden+of+vitiligo%3A+a+systematic+literature+review+of+quality-of-life+outcomes.&amp;publication_year=2022&amp;journal=J+Eur+Acad+Dermatol+Venereol&amp;pages=1507-1523&amp;doi=10.1111%2Fjdv.18129&amp;pmid=35366355" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Tsai H-R, Lu J-W, Chen L-Y, Chen T-L. Application of Janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta-analysis of clinical trials. <em>J Pers Med</em> 2021;11:279-279.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3390/jpm11040279" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33917069/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000643098200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Application+of+Janus+kinase+inhibitors+in+atopic+dermatitis%3A+an+updated+systematic+review+and+meta-analysis+of+clinical+trials.&amp;publication_year=2021&amp;journal=J+Pers+Med&amp;pages=279-279&amp;doi=10.3390%2Fjpm11040279&amp;pmid=33917069" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Lee JH, Kwon HS, Jung HM, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. <em>JAMA Dermatol</em> 2019;155:929-938.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamadermatol.2019.0696" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31141108/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000482438400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+outcomes+of+topical+calcineurin+inhibitor+therapy+for+patients+with+vitiligo%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2019&amp;journal=JAMA+Dermatol&amp;pages=929-938&amp;doi=10.1001%2Fjamadermatol.2019.0696&amp;pmid=31141108" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. <em>Blood</em> 2010;115:3109-3117.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2009-04-214957" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20130243/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000276689800017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms.&amp;publication_year=2010&amp;journal=Blood&amp;pages=3109-3117&amp;doi=10.1182%2Fblood-2009-04-214957&amp;pmid=20130243" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Hamzavi I, Rosmarin D, Harris JE, et al. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: descriptive subgroup analyses from a phase 2, randomized, double-blind trial. <em>J Am Acad Dermatol</em> 2022;86:1398-1401.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2021.05.047" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34089797/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000830075500020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+ruxolitinib+cream+in+vitiligo+by+patient+characteristics+and+affected+body+areas%3A+descriptive+subgroup+analyses+from+a+phase+2%2C+randomized%2C+double-blind+trial.&amp;publication_year=2022&amp;journal=J+Am+Acad+Dermatol&amp;pages=1398-1401&amp;doi=10.1016%2Fj.jaad.2021.05.047&amp;pmid=34089797" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">Costin G-E, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. <em>FASEB J</em> 2007;21:976-994.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1096/fj.06-6649rev" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17242160/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245650400003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+skin+pigmentation%3A+melanocytes+modulate+skin+color+in+response+to+stress.&amp;publication_year=2007&amp;journal=FASEB+J&amp;pages=976-994&amp;doi=10.1096%2Ffj.06-6649rev&amp;pmid=17242160" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/387/16"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">387</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">16</span></span> • <span property="datePublished">October 20, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1445</span>-<span property="pageEnd">1455</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2118828" class="core-component-translation hidden"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: October 19, 2022</div><div><b class="core-label">Published in issue</b>: October 20, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/adolescent-medicine" alt="View article keyword Adolescent Medicine" data-interactiontype="article_recirculation_click">Adolescent Medicine</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/allergy-immunology-general" alt="View article keyword Allergy/Immunology General" data-interactiontype="article_recirculation_click">Allergy/Immunology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/autoimmune-disease" alt="View article keyword Autoimmune Disease" data-interactiontype="article_recirculation_click">Autoimmune Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/clinical-medicine-general" alt="View article keyword Clinical Medicine General" data-interactiontype="article_recirculation_click">Clinical Medicine General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/dermatology-general" alt="View article keyword Dermatology General" data-interactiontype="article_recirculation_click">Dermatology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/inflammatory-disease" alt="View article keyword Inflammatory Disease" data-interactiontype="article_recirculation_click">Inflammatory Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">David</span> <span property="familyName">Rosmarin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thierry</span> <span property="familyName">Passeron</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-0797-6570" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-0797-6570</a></span>, <span property="author" typeof="Person"><span property="givenName">Amit G.</span> <span property="familyName">Pandya</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pearl</span> <span property="familyName">Grimes</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John E.</span> <span property="familyName">Harris</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Seemal R.</span> <span property="familyName">Desai</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mark</span> <span property="familyName">Lebwohl</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mireille</span> <span property="familyName">Ruer-Mulard</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Julien</span> <span property="familyName">Seneschal</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Albert</span> <span property="familyName">Wolkerstorfer</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Deanna</span> <span property="familyName">Kornacki</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kang</span> <span property="familyName">Sun</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kathleen</span> <span property="familyName">Butler</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Khaled</span> <span property="familyName">Ezzedine</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, for <span property="author" typeof="Person">the TRuE-V Study Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre Méditerranéen de Médecine Moléculaire, Université Côte d’Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, and Centre National de la Recherche Scientifique Unité Mixte de Recherche 5164, ImmunoConcept, Université de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Université Paris-Est Créteil Val de Marne, Paris (K.E.) — all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) — both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) — both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount Sinai, New York (M.L.); Amsterdam University Medical Center, Amsterdam (A.W.); and Incyte, Wilmington, DE (D.K., K.S., K.B.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Rosmarin can be contacted at <a href="mailto:drosmarin@tuftsmedicalcenter.org">drosmarin@tuftsmedicalcenter.org</a> or at Tufts Medical Center, 800 Washington St., P.O. Box 114, Boston, MA 02111.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the TRuE-V Study Group investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">143</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2118828" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="10fefbda-329b-8093-3e33-be2f2d43b0b7"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137434893" style="display:inline-block;">
                <img alt="Article has an altmetric score of 661" src="https://badges.altmetric.com/?size=320&amp;score=661&amp;types=mmbvtttw" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137434893">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_10fefbda-329b-8093-3e33-be2f2d43b0b7" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137434893&amp;tab=news">
          Picked up by <b>77</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137434893&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137434893&amp;tab=twitter">
          Posted by <b>89</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137434893&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137434893&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>166</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6f09145da00fb-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2118828"> <input type="hidden" name="downloadFileName" value="csp_387_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-16%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2118828%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="143" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Linxuan Wu, </li><li class="list-inline-item cited-by__entry__author">Tingrui Han, </li><li class="list-inline-item cited-by__entry__author">Yinghan Wang, </li><li class="list-inline-item cited-by__entry__author">Shuli Li, </li><li class="list-inline-item cited-by__entry__author">Chunying Li, </li></ul><span class="cited-by__entry__title">Epigenetic regulation in vitiligo: mechanisms, challenges, and therapeutic opportunities, </span><span class="cited-by__entry__series-title">Current Opinion in Immunology, </span><span class="cited-by__entry__volume"><strong>95</strong>, </span><span class="cited-by__entry__page-range">(102580), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.coi.2025.102580" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.coi.2025.102580</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.coi.2025.102580" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Laura Galissi, </li><li class="list-inline-item cited-by__entry__author">Tristan Benoît, </li><li class="list-inline-item cited-by__entry__author">Ribal Merhi, </li><li class="list-inline-item cited-by__entry__author">Claire Drullion, </li><li class="list-inline-item cited-by__entry__author">Nicolas Andreu, </li><li class="list-inline-item cited-by__entry__author">Khaled Ezzedine, </li><li class="list-inline-item cited-by__entry__author">Thomas Darde, </li><li class="list-inline-item cited-by__entry__author">Katia Boniface, </li><li class="list-inline-item cited-by__entry__author">Julien Seneschal, </li></ul><span class="cited-by__entry__title">Clinical heterogeneity in vitiligo: Identification of clinical markers based patient clusters, </span><span class="cited-by__entry__series-title">Journal of the European Academy of Dermatology and Venereology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/jdv.20785" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/jdv.20785</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/jdv.20785" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">N. N. Murashkin, </li><li class="list-inline-item cited-by__entry__author">T.  A. Gorislavskaia, </li></ul><span class="cited-by__entry__title">Efficacy and safety of janus kinase inhibitors in the treatment of alopecia areata in children, </span><span class="cited-by__entry__series-title">Medical alphabet, </span><span class="cited-by__entry__issue">8, </span><span class="cited-by__entry__page-range">(40-44), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.33667/2078-5631-2025-8-40-44" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.33667/2078-5631-2025-8-40-44</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.33667/2078-5631-2025-8-40-44" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jose L. LÓPEZ-ESTEBARANZ, </li><li class="list-inline-item cited-by__entry__author">Elena GARCÍA-ZAMORA, </li><li class="list-inline-item cited-by__entry__author">Joseph S. GRIFFITHS-ACHA, </li></ul><span class="cited-by__entry__title">Management of vitiligo: a promising future, </span><span class="cited-by__entry__series-title">Italian Journal of Dermatology and Venereology, </span><span class="cited-by__entry__volume"><strong>160</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.23736/S2784-8671.25.08112-5" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.23736/S2784-8671.25.08112-5</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.23736/S2784-8671.25.08112-5" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">A. Duplaine, </li><li class="list-inline-item cited-by__entry__author">J. Tannous, </li><li class="list-inline-item cited-by__entry__author">J. Seneschal, </li><li class="list-inline-item cited-by__entry__author">K. Ezzedine, </li><li class="list-inline-item cited-by__entry__author">T. Passeron, </li><li class="list-inline-item cited-by__entry__author">N. Dupin, </li><li class="list-inline-item cited-by__entry__author">G. Quereux, </li><li class="list-inline-item cited-by__entry__author">M. Beylot-Barry, </li><li class="list-inline-item cited-by__entry__author">O. Chosidow, </li><li class="list-inline-item cited-by__entry__author">B. Guillot, </li></ul><span class="cited-by__entry__title">Value of tacrolimus 0.1% in the treatment of vitiligo in the era of targeted therapy, </span><span class="cited-by__entry__series-title">Annales de Dermatologie et de Vénéréologie, </span><span class="cited-by__entry__volume"><strong>152</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(103352), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.annder.2025.103352" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.annder.2025.103352</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.annder.2025.103352" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Vincenzo Picone, </li><li class="list-inline-item cited-by__entry__author">Luigi Coronella, </li><li class="list-inline-item cited-by__entry__author">Massimiliano Scalvenzi, </li><li class="list-inline-item cited-by__entry__author">Cataldo Patruno, </li><li class="list-inline-item cited-by__entry__author">Ludovica Lizzi, </li><li class="list-inline-item cited-by__entry__author">Marianna Cimmino, </li><li class="list-inline-item cited-by__entry__author">Maddalena Napolitano, </li></ul><span class="cited-by__entry__title">Potential future biologic therapies for the treatment of vitiligo: focus on phase 2 and 3, </span><span class="cited-by__entry__series-title">Expert Review of Clinical Immunology, </span><span class="cited-by__entry__page-range">(1-11), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/1744666X.2025.2512452" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/1744666X.2025.2512452</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/1744666X.2025.2512452" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Prashant S. Giri, </li><li class="list-inline-item cited-by__entry__author">Shivani Patel, </li><li class="list-inline-item cited-by__entry__author">Foram Thakor, </li><li class="list-inline-item cited-by__entry__author">Mitesh Dwivedi, </li></ul><span class="cited-by__entry__title">Meta-analysis for alterations of IFN-γ, TNF-α and granzyme B levels in vitiligo patients, </span><span class="cited-by__entry__series-title">Expert Review of Clinical Immunology, </span><span class="cited-by__entry__page-range">(1-14), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/1744666X.2025.2510491" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/1744666X.2025.2510491</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/1744666X.2025.2510491" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Qiyu Wang, </li><li class="list-inline-item cited-by__entry__author">Jingwei Yuan, </li><li class="list-inline-item cited-by__entry__author">Mengdi Zhang, </li><li class="list-inline-item cited-by__entry__author">Haiyan Jia, </li><li class="list-inline-item cited-by__entry__author">Hongjie Lu, </li><li class="list-inline-item cited-by__entry__author">Yan Wu, </li></ul><span class="cited-by__entry__title">Bioinformatics meets machine learning: identifying circulating biomarkers for vitiligo across blood and tissues, </span><span class="cited-by__entry__series-title">Frontiers in Immunology, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fimmu.2025.1543355" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fimmu.2025.1543355</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fimmu.2025.1543355" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alzahra A. Mohammed, </li><li class="list-inline-item cited-by__entry__author">Anna S. Lengyel, </li><li class="list-inline-item cited-by__entry__author">Fanni A. Meznerics, </li><li class="list-inline-item cited-by__entry__author">István Szondy, </li><li class="list-inline-item cited-by__entry__author">Anna Walter, </li><li class="list-inline-item cited-by__entry__author">Bence Szabó, </li><li class="list-inline-item cited-by__entry__author">Dorottya Pál, </li><li class="list-inline-item cited-by__entry__author">Adrienn Bojtor, </li><li class="list-inline-item cited-by__entry__author">András Bánvölgyi, </li><li class="list-inline-item cited-by__entry__author">Norbert Kiss, </li><li class="list-inline-item cited-by__entry__author">Péter Hegyi, </li><li class="list-inline-item cited-by__entry__author">Lajos V. Kemény, </li><li class="list-inline-item cited-by__entry__author">Zsuzsanna Kurgyis, </li></ul><span class="cited-by__entry__title">Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis, </span><span class="cited-by__entry__series-title">Dermatology and Therapy, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">7, </span><span class="cited-by__entry__page-range">(1657-1679), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s13555-025-01397-z" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s13555-025-01397-z</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s13555-025-01397-z" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Elif Demirci Saadet, </li><li class="list-inline-item cited-by__entry__author">Belma Tursen, </li></ul><span class="cited-by__entry__title">Safety, Toxicity Profile and Side Effects, </span><span class="cited-by__entry__series-title">Jak-Inhibitors in Dermatology, </span><span class="cited-by__entry__page-range">(131-139), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/978-3-031-84274-0_16" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/978-3-031-84274-0_16</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/978-3-031-84274-0_16" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-16%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2118828%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2118828" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2118828" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2118828.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2118828_f0.jpg"><img src="/cms/10.1056/NEJMoa2118828/asset/dbb9ea1e-44ab-468b-a14e-93993bfebe48/assets/images/large/nejmoa2118828_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2118828_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2118828/asset/a9e84a5a-74cb-40fa-a9d2-417c911ee071/assets/images/large/nejmoa2118828_t1.jpg" height="3438" width="1900" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>TRuE-V1</span></th><th class="txxr-borders" colspan="3"><span>TRuE-V2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Vehicle<br>(N=109)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=221)</th><th class="xxxx-borders">Total<br>(N=330)</th><th class="xxxx-borders">Vehicle<br>(N=115)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=228)</th><th class="xxxr-borders">Total<br>(N=343)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">39.7±16.7</td><td class="xxxx-borders shading">40.5±15.4</td><td class="xxxx-borders shading">40.2±15.9</td><td class="xxxx-borders shading">39.8±12.1</td><td class="xxxx-borders shading">38.4±15.2</td><td class="xxxr-borders shading">38.9±14.3</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Age group — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">12–17 yr</td><td class="xxxx-borders shading">11 (10.1)</td><td class="xxxx-borders shading">25 (11.3)</td><td class="xxxx-borders shading">36 (10.9)</td><td class="xxxx-borders shading">6 (5.2)</td><td class="xxxx-borders shading">30 (13.2)</td><td class="xxxr-borders shading">36 (10.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">18–64 yr</td><td class="xxxx-borders">85 (78.0)</td><td class="xxxx-borders">180 (81.4)</td><td class="xxxx-borders">265 (80.3)</td><td class="xxxx-borders">106 (92.2)</td><td class="xxxx-borders">186 (81.6)</td><td class="xxxr-borders">292 (85.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥65 yr</td><td class="xxxx-borders shading">13 (11.9)</td><td class="xxxx-borders shading">16 (7.2)</td><td class="xxxx-borders shading">29 (8.8)</td><td class="xxxx-borders shading">3 (2.6)</td><td class="xxxx-borders shading">12 (5.3)</td><td class="xxxr-borders shading">15 (4.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">50 (45.9)</td><td class="xxxx-borders">136 (61.5)</td><td class="xxxx-borders">186 (56.4)</td><td class="xxxx-borders">60 (52.2)</td><td class="xxxx-borders">112 (49.1)</td><td class="xxxr-borders">172 (50.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">96 (88.1)</td><td class="xxxx-borders">180 (81.4)</td><td class="xxxx-borders">276 (83.6)</td><td class="xxxx-borders">93 (80.9)</td><td class="xxxx-borders">182 (79.8)</td><td class="xxxr-borders">275 (80.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">11 (5.0)</td><td class="xxxx-borders shading">15 (4.5)</td><td class="xxxx-borders shading">5 (4.3)</td><td class="xxxx-borders shading">12 (5.3)</td><td class="xxxr-borders shading">17 (5.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">5 (2.3)</td><td class="xxxx-borders">9 (2.7)</td><td class="xxxx-borders">7 (6.1)</td><td class="xxxx-borders">12 (5.3)</td><td class="xxxr-borders">19 (5.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">2 (1.8)</td><td class="xxxx-borders shading">9 (4.1)</td><td class="xxxx-borders shading">11 (3.3)</td><td class="xxxx-borders shading">7 (6.1)</td><td class="xxxx-borders shading">19 (8.3)</td><td class="xxxr-borders shading">26 (7.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Not reported</td><td class="xxxx-borders">3 (2.8)</td><td class="xxxx-borders">16 (7.2)</td><td class="xxxx-borders">19 (5.8)</td><td class="xxxx-borders">3 (2.6)</td><td class="xxxx-borders">3 (1.3)</td><td class="xxxr-borders">6 (1.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Fitzpatrick skin type — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">I</td><td class="xxxx-borders">3 (2.8)</td><td class="xxxx-borders">10 (4.5)</td><td class="xxxx-borders">13 (3.9)</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxr-borders">3 (0.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">II</td><td class="xxxx-borders shading">40 (36.7)</td><td class="xxxx-borders shading">74 (33.5)</td><td class="xxxx-borders shading">114 (34.5)</td><td class="xxxx-borders shading">32 (27.8)</td><td class="xxxx-borders shading">57 (25.0)</td><td class="xxxr-borders shading">89 (25.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">III</td><td class="xxxx-borders">43 (39.4)</td><td class="xxxx-borders">89 (40.3)</td><td class="xxxx-borders">132 (40.0)</td><td class="xxxx-borders">45 (39.1)</td><td class="xxxx-borders">89 (39.0)</td><td class="xxxr-borders">134 (39.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">IV</td><td class="xxxx-borders shading">15 (13.8)</td><td class="xxxx-borders shading">34 (15.4)</td><td class="xxxx-borders shading">49 (14.8)</td><td class="xxxx-borders shading">25 (21.7)</td><td class="xxxx-borders shading">55 (24.1)</td><td class="xxxr-borders shading">80 (23.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">V</td><td class="xxxx-borders">7 (6.4)</td><td class="xxxx-borders">11 (5.0)</td><td class="xxxx-borders">18 (5.5)</td><td class="xxxx-borders">10 (8.7)</td><td class="xxxx-borders">17 (7.5)</td><td class="xxxr-borders">27 (7.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">VI</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">3 (1.4)</td><td class="xxxx-borders shading">4 (1.2)</td><td class="xxxx-borders shading">2 (1.7)</td><td class="xxxx-borders shading">8 (3.5)</td><td class="xxxr-borders shading">10 (2.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Geographic region — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">North America</td><td class="xxxx-borders shading">73 (67.0)</td><td class="xxxx-borders shading">147 (66.5)</td><td class="xxxx-borders shading">220 (66.7)</td><td class="xxxx-borders shading">83 (72.2)</td><td class="xxxx-borders shading">160 (70.2)</td><td class="xxxr-borders shading">243 (70.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Europe</td><td class="xxxx-borders">36 (33.0)</td><td class="xxxx-borders">74 (33.5)</td><td class="xxxx-borders">110 (33.3)</td><td class="xxxx-borders">32 (27.8)</td><td class="xxxx-borders">68 (29.8)</td><td class="xxxr-borders">100 (29.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">F-VASI<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">1.00±0.59</td><td class="xxxx-borders shading">0.93±0.58</td><td class="xxxx-borders shading">0.95±0.59</td><td class="xxxx-borders shading">0.83±0.52</td><td class="xxxx-borders shading">0.90±0.52</td><td class="xxxr-borders shading">0.88±0.52</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">T-VASI<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">6.42±1.92</td><td class="xxxx-borders">6.49±2.02</td><td class="xxxx-borders">6.47±1.99</td><td class="xxxx-borders">7.02±2.20</td><td class="xxxx-borders">6.84±2.06</td><td class="xxxr-borders">6.90±2.10</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Facial BSA affected by vitiligo — %<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">1.15±0.71</td><td class="xxxx-borders shading">1.05±0.69</td><td class="xxxx-borders shading">1.09±0.70</td><td class="xxxx-borders shading">0.92±0.57</td><td class="xxxx-borders shading">0.98±0.57</td><td class="xxxr-borders shading">0.96±0.57</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Total BSA affected by vitiligo — %</td><td class="xxxx-borders">7.22±2.01</td><td class="xxxx-borders">7.28±2.03</td><td class="xxxx-borders">7.26±2.02</td><td class="xxxx-borders">7.68±2.04</td><td class="xxxx-borders">7.44±2.01</td><td class="xxxr-borders">7.52±2.02</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Duration of disease — yr</td><td class="xxxx-borders shading">13.2±10.0</td><td class="xxxx-borders shading">13.9±11.7</td><td class="xxxx-borders shading">13.6±11.1</td><td class="xxxx-borders shading">16.0±11.6</td><td class="xxxx-borders shading">15.9±12.1</td><td class="xxxr-borders shading">15.9±11.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Received diagnosis in childhood — no. (%)</td><td class="xxxx-borders">34 (31.2)</td><td class="xxxx-borders">72 (32.6)</td><td class="xxxx-borders">106 (32.1)</td><td class="xxxx-borders">43 (37.4)</td><td class="xxxx-borders">96 (42.1)</td><td class="xxxr-borders">139 (40.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Disease stability — no. (%)<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stable</td><td class="xxxx-borders">80 (73.4)</td><td class="xxxx-borders">165 (74.7)</td><td class="xxxx-borders">245 (74.2)</td><td class="xxxx-borders">88 (76.5)</td><td class="xxxx-borders">166 (72.8)</td><td class="xxxr-borders">254 (74.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Progressive</td><td class="xxxx-borders shading">29 (26.6)</td><td class="xxxx-borders shading">56 (25.3)</td><td class="xxxx-borders shading">85 (25.8)</td><td class="xxxx-borders shading">27 (23.5)</td><td class="xxxx-borders shading">62 (27.2)</td><td class="xxxr-borders shading">89 (25.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Other autoimmune disorders — no. (%)<a href="#core-t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">18 (16.5)</td><td class="xxxx-borders">53 (24.0)</td><td class="xxxx-borders">71 (21.5)</td><td class="xxxx-borders">18 (15.7)</td><td class="xxxx-borders">37 (16.2)</td><td class="xxxr-borders">55 (16.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Thyroid disorders</td><td class="xxxx-borders shading">17 (15.6)</td><td class="xxxx-borders shading">50 (22.6)</td><td class="xxxx-borders shading">67 (20.3)</td><td class="xxxx-borders shading">15 (13.0)</td><td class="xxxx-borders shading">35 (15.4)</td><td class="xxxr-borders shading">50 (14.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Juvenile diabetes mellitus</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pernicious anemia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">5 (2.3)</td><td class="xxxx-borders">6 (1.8)</td><td class="xxxx-borders">6 (5.2)</td><td class="xxxx-borders">5 (2.2)</td><td class="xxxr-borders">11 (3.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Previous therapy — no. (%)<a href="#core-t1fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders shading">61 (56.0)</td><td class="xxxx-borders shading">131 (59.3)</td><td class="xxxx-borders shading">192 (58.2)</td><td class="xxxx-borders shading">76 (66.1)</td><td class="xxxx-borders shading">143 (62.7)</td><td class="xxxr-borders shading">219 (63.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Topical calcineurin inhibitors</td><td class="xxxx-borders">31 (28.4)</td><td class="xxxx-borders">72 (32.6)</td><td class="xxxx-borders">103 (31.2)</td><td class="xxxx-borders">37 (32.2)</td><td class="xxxx-borders">74 (32.5)</td><td class="xxxr-borders">111 (32.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Topical glucocorticoids</td><td class="xxxx-borders shading">28 (25.7)</td><td class="xxxx-borders shading">67 (30.3)</td><td class="xxxx-borders shading">95 (28.8)</td><td class="xxxx-borders shading">28 (24.3)</td><td class="xxxx-borders shading">66 (28.9)</td><td class="xxxr-borders shading">94 (27.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">NB-UVB phototherapy</td><td class="xxxx-borders">20 (18.3)</td><td class="xxxx-borders">41 (18.6)</td><td class="xxxx-borders">61 (18.5)</td><td class="xxxx-borders">27 (23.5)</td><td class="xxxx-borders">52 (22.8)</td><td class="xxxr-borders">79 (23.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Excimer laser therapy</td><td class="xxxx-borders shading">8 (7.3)</td><td class="xxxx-borders shading">18 (8.1)</td><td class="xxxx-borders shading">26 (7.9)</td><td class="xxxx-borders shading">14 (12.2)</td><td class="xxxx-borders shading">16 (7.0)</td><td class="xxxr-borders shading">30 (8.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">PUVA photochemotherapy</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">8 (3.6)</td><td class="xxxx-borders">12 (3.6)</td><td class="xxxx-borders">8 (7.0)</td><td class="xxxx-borders">15 (6.6)</td><td class="xxxr-borders">23 (6.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Vitamin D derivatives</td><td class="xxxx-borders shading">2 (1.8)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxx-borders shading">6 (1.8)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Other</td><td class="xbxx-borders">11 (10.1)</td><td class="xbxx-borders">24 (10.9)</td><td class="xbxx-borders">35 (10.6)</td><td class="xbxx-borders">14 (12.2)</td><td class="xbxx-borders">34 (14.9)</td><td class="xbxr-borders">48 (14.0)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. BSA denotes body-surface area, NB-UVB narrow-band ultraviolet B, PUVA psoralen and ultraviolet A, TRuE-V1 Topical Ruxolitinib Evaluation in Vitiligo Study 1, and TRuE-V2 Topical Ruxolitinib Evaluation in Vitiligo Study 2.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race and ethnic group were reported by the patient. “Other” includes American Indian or Alaska Native, Native Hawaiian or Pacific Islander, and other.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Fitzpatrick skin types range from I to VI: type I indicates pale white; type II, white; type III, light brown; type IV, moderate brown; type V, dark brown; and type VI, deeply pigmented dark brown to black.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Scores on the facial Vitiligo Area Scoring Index (F-VASI) range from 0 to 3, with higher scores indicating a greater area of facial depigmentation.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Scores on the total Vitiligo Area Scoring Index (T-VASI) range from 0 to 100, with higher scores indicating a greater area of total body depigmentation.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Shown is the percentage of total BSA.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">The determination of disease stability was based on investigator judgment.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">Patients could report multiple autoimmune disorders.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="core-t1fn9" role="paragraph" data-to-manipulate="true">Patients could have used multiple previous lines of therapy. “Other” includes other types of phototherapy, oral glucocorticoids, surgical techniques, and other.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Safety Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2118828/asset/ba988464-0c88-4f7b-9cf1-f8ae3814495c/assets/images/large/nejmoa2118828_t2.jpg" height="1092" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders" colspan="4"><span>TRuE-V1</span></th><th class="txxr-borders" colspan="4"><span>TRuE-V2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Vehicle<br>(N=109)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=221)</th><th class="xxxx-borders">Relative Risk (95% CI)</th><th class="xxxx-borders">P Value</th><th class="xxxx-borders">Vehicle<br>(N=109)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=222)</th><th class="xxxx-borders">Relative Risk (95% CI)</th><th class="xxxr-borders">P Value</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">F-VASI75 response at wk 24 — % (95% CI)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">7.4 (2.2 to 12.6)</td><td class="xxxx-borders">29.8 (23.5 to 36.1)</td><td class="xxxx-borders">4.0 (1.9 to 8.4)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">11.4 (5.2 to 17.7)</td><td class="xxxx-borders">30.9 (24.5 to 37.3)</td><td class="xxxx-borders">2.7 (1.5 to 4.9)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Key secondary end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">F-VASI50 response at wk 24 — % (95% CI)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">16.9 (9.3 to 24.6)</td><td class="xxxx-borders">51.2 (44.4 to 58.0)</td><td class="xxxx-borders">3.0 (1.9 to 4.8)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">20.9 (12.9 to 28.9)</td><td class="xxxx-borders">51.4 (44.6 to 58.3)</td><td class="xxxx-borders">2.5 (1.6 to 3.7)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">F-VASI90 response at wk 24 — % (95% CI)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">2.2 (0 to 5.1)</td><td class="xxxx-borders shading">15.3 (10.4 to 20.2)</td><td class="xxxx-borders shading">7.3 (1.8 to 29.5)</td><td class="xxxx-borders shading">0.004</td><td class="xxxx-borders shading">1.3 (0 to 3.8)</td><td class="xxxx-borders shading">16.3 (11.2 to 21.5)</td><td class="xxxx-borders shading">13.1 (1.9 to 90.2)</td><td class="xxxr-borders shading">0.006</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">T-VASI50 response at wk 24 — % (95% CI)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">5.1 (0.6 to 9.7)</td><td class="xxxx-borders">20.6 (15.2 to 26.0)</td><td class="xxxx-borders">4.1 (1.6 to 10.5)</td><td class="xxxx-borders">0.002</td><td class="xxxx-borders">6.8 (1.9 to 11.7)</td><td class="xxxx-borders">23.9 (18.1 to 29.8)</td><td class="xxxx-borders">3.5 (1.7 to 7.5)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">VNS response at wk 24 — % (95% CI)<a href="#core-t2fn2" role="doc-noteref">†</a><a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">3.3 (0 to 6.9)</td><td class="xxxx-borders shading">24.5 (18.5 to 30.4)</td><td class="xxxx-borders shading">7.5 (2.4 to 23.5)</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">4.9 (0.7 to 9.2)</td><td class="xxxx-borders shading">20.5 (14.9 to 26.1)</td><td class="xxxx-borders shading">4.2 (1.7 to 10.2)</td><td class="xxxr-borders shading">0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">LSM percentage change from baseline in facial BSA affected by vitiligo at wk 24 (95% CI)<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xbxx-borders">–9.5 (–15.9 to –3.2)</td><td class="xbxx-borders">–28.9 (–33.2 to –24.5)</td><td class="xbxx-borders">NA</td><td class="xbxx-borders">&lt;0.001</td><td class="xbxx-borders">–7.0 (–14.5 to 0.5)</td><td class="xbxx-borders">–26.4 (–31.5 to –21.4)</td><td class="xbxx-borders">NA</td><td class="xbxr-borders">&lt;0.001</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">F-VASI50 denotes a decrease (improvement) of at least 50% in the F-VASI from baseline, F-VASI75 a decrease of at least 75% in the F-VASI from baseline, F-VASI90 a decrease of at least 90% in the F-VASI from baseline, NA not applicable, and T-VASI50 a decrease of at least 50% in the T-VASI from baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Multiple imputation was applied to account for missing values.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">A Vitiligo Noticeability Scale (VNS) response was defined as a rating of a lot less noticeable or no longer noticeable.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">An analysis of covariance model was applied to determine least-squares mean (LSM) and P value.</div></div></div></figcaption></a><figcaption><div class="caption">Primary and Key Secondary Efficacy End Points (Double-Blind Period; Modified Intention-to-Treat Population).<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2118828/asset/d7369af1-2173-439d-aefb-f6acf9615744/assets/images/large/nejmoa2118828_t3.jpg" height="2765" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="4"><span>TRuE-V1</span></th><th class="txxr-borders" colspan="4"><span>TRuE-V2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>Double-Blind Period<a href="#core-t3fn1" role="doc-noteref">*</a></span></th><th class="xxxx-borders" colspan="2"><span>Extension Period<a href="#core-t3fn2" role="doc-noteref">†</a></span></th><th class="xxxx-borders" colspan="2"><span>Double-Blind Period<a href="#core-t3fn1" role="doc-noteref">*</a></span></th><th class="xxxr-borders" colspan="2"><span>Extension Period<a href="#core-t3fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Vehicle<br>(N=109)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=221)</th><th class="xxxx-borders">Vehicle to 1.5% Ruxolitinib Cream<br>(N=90)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=193)</th><th class="xxxx-borders">Vehicle<br>(N=115)</th><th class="xxxx-borders">1.5% Ruxolitinib Cream<br>(N=228)</th><th class="xxxx-borders">Vehicle to 1.5% Ruxolitinib Cream<br>(N=98)</th><th class="xxxr-borders">1.5% Ruxolitinib Cream<br>(N=199)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="8"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">42 (38.5)</td><td class="xxxx-borders shading">101 (45.7)</td><td class="xxxx-borders shading">31 (34.4)</td><td class="xxxx-borders shading">65 (33.7)</td><td class="xxxx-borders shading">39 (33.9)</td><td class="xxxx-borders shading">114 (50.0)</td><td class="xxxx-borders shading">38 (38.8)</td><td class="xxxr-borders shading">82 (41.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Most common adverse events<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Covid-19<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">5 (4.6)</td><td class="xxxx-borders shading">3 (1.4)</td><td class="xxxx-borders shading">1 (1.1)</td><td class="xxxx-borders shading">11 (5.7)</td><td class="xxxx-borders shading">2 (1.7)</td><td class="xxxx-borders shading">10 (4.4)</td><td class="xxxx-borders shading">5 (5.1)</td><td class="xxxr-borders shading">9 (4.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Application-site acne</td><td class="xxxx-borders">0</td><td class="xxxx-borders">13 (5.9)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.5)</td><td class="xxxx-borders">3 (2.6)</td><td class="xxxx-borders">13 (5.7)</td><td class="xxxx-borders">5 (5.1)</td><td class="xxxr-borders">3 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">9 (4.1)</td><td class="xxxx-borders shading">2 (2.2)</td><td class="xxxx-borders shading">3 (1.6)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">10 (4.4)</td><td class="xxxx-borders shading">3 (3.1)</td><td class="xxxr-borders shading">4 (2.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Headache</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxx-borders">6 (2.7)</td><td class="xxxx-borders">2 (2.2)</td><td class="xxxx-borders">3 (1.6)</td><td class="xxxx-borders">4 (3.5)</td><td class="xxxx-borders">11 (4.8)</td><td class="xxxx-borders">1 (1.0)</td><td class="xxxr-borders">6 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Application-site pruritus</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">11 (5.0)</td><td class="xxxx-borders shading">1 (1.1)</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">2 (1.7)</td><td class="xxxx-borders shading">12 (5.3)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders">5 (4.6)</td><td class="xxxx-borders">6 (2.7)</td><td class="xxxx-borders">3 (3.3)</td><td class="xxxx-borders">2 (1.0)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (3.1)</td><td class="xxxx-borders">2 (2.0)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Sinusitis</td><td class="xxxx-borders shading">3 (2.8)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxx-borders shading">1 (1.1)</td><td class="xxxx-borders shading">3 (1.6)</td><td class="xxxx-borders shading">2 (1.7)</td><td class="xxxx-borders shading">6 (2.6)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Application-site dermatitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">5 (2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Application-site rash</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">5 (2.3)</td><td class="xxxx-borders hanging11 shading">1 (1.1)</td><td class="xxxx-borders hanging11 shading">1 (0.5)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Oral herpes</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders hanging11">2 (2.2)</td><td class="xxxx-borders hanging11">2 (1.0)</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">3 (1.3)</td><td class="xxxx-borders">1 (1.0)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Urinary tract infection</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">5 (2.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxx-borders shading">1 (1.0)</td><td class="xxxr-borders shading">2 (1.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Acne</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">3 (3.3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxx-borders">1 (1.0)</td><td class="xxxr-borders">2 (1.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pyrexia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (2.2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Application-site exfoliation</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">5 (2.2)</td><td class="xxxx-borders">1 (1.0)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hypothyroidism</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (2.2)</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event related to trial agent<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">10 (9.2)</td><td class="xxxx-borders">38 (17.2)</td><td class="xxxx-borders">5 (5.6)</td><td class="xxxx-borders">7 (3.6)</td><td class="xxxx-borders">6 (5.2)</td><td class="xxxx-borders">28 (12.3)</td><td class="xxxx-borders">6 (6.1)</td><td class="xxxr-borders">12 (6.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Most common adverse events related to trial agent<a href="#core-t3fn3" role="doc-noteref">‡</a><a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Application-site acne</td><td class="xxxx-borders">0</td><td class="xxxx-borders">12 (5.4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.5)</td><td class="xxxx-borders">2 (1.7)</td><td class="xxxx-borders">10 (4.4)</td><td class="xxxx-borders">3 (3.1)</td><td class="xxxr-borders">3 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Application-site pruritus</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">11 (5.0)</td><td class="xxxx-borders shading">1 (1.1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1.7)</td><td class="xxxx-borders shading">10 (4.4)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Application-site exfoliation</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">5 (2.2)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event<a href="#core-t3fn6" role="doc-noteref">‖</a><a href="#core-t3fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">6 (2.7)</td><td class="xxxx-borders shading">1 (1.1)</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">2 (2.0)</td><td class="xxxr-borders shading">2 (1.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Adverse event leading to discontinuation of trial agent</td><td class="xbxx-borders">1 (0.9)</td><td class="xbxx-borders">1 (0.5)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (0.4)</td><td class="xbxx-borders">0</td><td class="xbxr-borders">1 (0.5)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Adverse events during the double-blind period (up to week 24) are reported in the safety population (ruxolitinib-cream group and vehicle group).</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Adverse events during the open-label treatment extension period (after week 24) are reported in the treatment-extension evaluable population (ruxolitinib-cream group and vehicle-to-ruxolitinib-cream group).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Shown are events that occurred in more than 2% of the patients in any group.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">On the basis of the prevalence of coronavirus disease 2019 (Covid-19) at the time the trials were conducted, the incidence of Covid-19 was not considered to be relevant to ruxolitinib-cream application.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">The relatedness of the adverse event to the trial agent was determined by the investigator.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t3fn6" role="paragraph" data-to-manipulate="true">No serious adverse events were considered by investigators to be related to the trial agent according to criteria prespecified in the protocol.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t3fn7" role="paragraph" data-to-manipulate="true">In TRuE-V1, serious adverse events with application of ruxolitinib cream were anal fistula, appendicitis, concussion, hepatitis due to infectious mononucleosis, hypersensitivity, kidney contusion, myocarditis, prostate cancer, and subacute combined cord degeneration (in one patient each); hypersensitivity and subacute combined cord degeneration occurred in the same patient. In TRuE-V2, serious adverse events with ruxolitinib cream were appendiceal abscess, coronary-artery stenosis, joint dislocation, papillary thyroid cancer, rhabdomyolysis, and ureterolithiasis (in one patient each).</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events during the Double-Blind Period and Open-Label Treatment Extension Period.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2118828_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2118828</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. <em>J Am Acad Dermatol</em> 2017;77:1-13.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2016.10.048" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28619550/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403205000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+discoveries+in+the+pathogenesis+and+classification+of+vitiligo.&amp;publication_year=2017&amp;journal=J+Am+Acad+Dermatol&amp;pages=1-13&amp;doi=10.1016%2Fj.jaad.2016.10.048&amp;pmid=28619550" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] disease that results in skin depigmentation </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] functioning melanocytes in the epidermis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Boniface K, Seneschal J, Picardo M, Taïeb A. Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. <em>Clin Rev Allergy Immunol</em> 2018;54:52-67.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12016-017-8622-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28685247/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000424247300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vitiligo%3A+focus+on+clinical+aspects%2C+immunopathogenesis%2C+and+therapy.&amp;publication_year=2018&amp;journal=Clin+Rev+Allergy+Immunol&amp;pages=52-67&amp;doi=10.1007%2Fs12016-017-8622-7&amp;pmid=28685247" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] disease that results in skin depigmentation </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] functioning melanocytes in the epidermis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Morrison B, Burden-Teh E, Batchelor JM, Mead E, Grindlay D, Ratib S. Quality of life in people with vitiligo: a systematic review and meta-analysis. <em>Br J Dermatol</em> 2017;177(6):e338-e339.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjd.15933" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28869779/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000419479300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Quality+of+life+in+people+with+vitiligo%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2017&amp;journal=Br+J+Dermatol&amp;pages=e338-e339&amp;doi=10.1111%2Fbjd.15933&amp;pmid=28869779" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. <em>Am J Clin Dermatol</em> 2021;22:757-774.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40257-021-00631-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34554406/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000698537000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Psychosocial+effects+of+vitiligo%3A+a+systematic+literature+review.&amp;publication_year=2021&amp;journal=Am+J+Clin+Dermatol&amp;pages=757-774&amp;doi=10.1007%2Fs40257-021-00631-6&amp;pmid=34554406" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and reduced quality of life. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and extensive body-area involvement. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Rashighi M, Harris JE. Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. <em>Ann Transl Med</em> 2015;3:343-343.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26734651/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interfering+with+the+IFN-%CE%B3%2FCXCL10+pathway+to+develop+new+targeted+treatments+for+vitiligo.&amp;publication_year=2015&amp;journal=Ann+Transl+Med&amp;pages=343-343&amp;pmid=26734651" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] activator of transcription (STAT) pathway, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which drives melanocyte destruction. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Martins C, Migayron L, Drullion C, et al. Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling. <em>J Invest Dermatol</em> 2022;142(4):1194-1205.e7.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jid.2021.09.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34655610/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000771485000032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vitiligo+skin+T+cells+are+prone+to+produce+type+1+and+type+2+cytokines+to+induce+melanocyte+dysfunction+and+epidermal+inflammatory+response+through+Jak+signaling.&amp;publication_year=2022&amp;journal=J+Invest+Dermatol&amp;pages=1194-1205.e7&amp;doi=10.1016%2Fj.jid.2021.09.015&amp;pmid=34655610" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] activator of transcription (STAT) pathway, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which drives melanocyte destruction. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. <em>J Invest Dermatol</em> 2009;129:2220-2232.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/jid.2009.32" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19242513/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000268939700021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Autoimmune+destruction+of+skin+melanocytes+by+perilesional+T+cells+from+vitiligo+patients.&amp;publication_year=2009&amp;journal=J+Invest+Dermatol&amp;pages=2220-2232&amp;doi=10.1038%2Fjid.2009.32&amp;pmid=19242513" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Chen J, Li S, Li C. Mechanisms of melanocyte death in vitiligo. <em>Med Res Rev</em> 2021;41:1138-1166.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/med.21754" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33200838/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000589752800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mechanisms+of+melanocyte+death+in+vitiligo.&amp;publication_year=2021&amp;journal=Med+Res+Rev&amp;pages=1138-1166&amp;doi=10.1002%2Fmed.21754&amp;pmid=33200838" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Wang XX, Wang QQ, Wu JQ, et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. <em>Br J Dermatol</em> 2016;174:1318-1326.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjd.14416" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26801009/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000378047100028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+expression+of+CXCR3+and+its+ligands+in+patients+with+vitiligo+and+CXCL10+as+a+potential+clinical+marker+for+vitiligo.&amp;publication_year=2016&amp;journal=Br+J+Dermatol&amp;pages=1318-1326&amp;doi=10.1111%2Fbjd.14416&amp;pmid=26801009" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Ferrari SM, Fallahi P, Santaguida G, et al. Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis. <em>Autoimmun Rev</em> 2017;16:946-950.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.autrev.2017.07.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28698095/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410869200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Circulating+CXCL10+is+increased+in+non-segmental+vitiligo%2C+in+presence+or+absence+of+autoimmune+thyroiditis.&amp;publication_year=2017&amp;journal=Autoimmun+Rev&amp;pages=946-950&amp;doi=10.1016%2Fj.autrev.2017.07.006&amp;pmid=28698095" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8<sup>+</sup> T-cell accumulation in the skin. <em>J Invest Dermatol</em> 2012;132:1869-1876.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/jid.2011.463" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22297636/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000305492900019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+mouse+model+of+vitiligo+with+focused+epidermal+depigmentation+requires+IFN-%CE%B3+for+autoreactive+CD8%2B+T-cell+accumulation+in+the+skin.&amp;publication_year=2012&amp;journal=J+Invest+Dermatol&amp;pages=1869-1876&amp;doi=10.1038%2Fjid.2011.463&amp;pmid=22297636" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Regazzetti C, Joly F, Marty C, et al. Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients. <em>J Invest Dermatol</em> 2015;135:3105-3114.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/jid.2015.335" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26322948/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365181100030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Transcriptional+analysis+of+vitiligo+skin+reveals+the+alteration+of+WNT+pathway%3A+a+promising+target+for+repigmenting+vitiligo+patients.&amp;publication_year=2015&amp;journal=J+Invest+Dermatol&amp;pages=3105-3114&amp;doi=10.1038%2Fjid.2015.335&amp;pmid=26322948" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Bergqvist C, Ezzedine K. Vitiligo: a focus on pathogenesis and its therapeutic implications. <em>J Dermatol</em> 2021;48:252-270.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/1346-8138.15743" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33404102/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605018200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vitiligo%3A+a+focus+on+pathogenesis+and+its+therapeutic+implications.&amp;publication_year=2021&amp;journal=J+Dermatol&amp;pages=252-270&amp;doi=10.1111%2F1346-8138.15743&amp;pmid=33404102" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. <em>J Am Acad Dermatol</em> 2017;76(6):1054-1060.e1.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2017.02.049" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28390737/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000402797000024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+vitiligo+with+the+topical+Janus+kinase+inhibitor+ruxolitinib.&amp;publication_year=2017&amp;journal=J+Am+Acad+Dermatol&amp;pages=1054-1060.e1&amp;doi=10.1016%2Fj.jaad.2017.02.049&amp;pmid=28390737" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. <em>J Am Acad Dermatol</em> 2017;77(4):675-682.e1.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2017.05.043" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28823882/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410627400022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Repigmentation+in+vitiligo+using+the+Janus+kinase+inhibitor+tofacitinib+may+require+concomitant+light+exposure.&amp;publication_year=2017&amp;journal=J+Am+Acad+Dermatol&amp;pages=675-682.e1&amp;doi=10.1016%2Fj.jaad.2017.05.043&amp;pmid=28823882" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] after treatment with JAK inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r31" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] or with combination therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Joshipura D, Alomran A, Zancanaro P, Rosmarin D. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. <em>J Am Acad Dermatol</em> 2018;78(6):1205-1207.e1.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2018.02.023" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29438765/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000432494000033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+vitiligo+with+the+topical+Janus+kinase+inhibitor+ruxolitinib%3A+a+32-week+open-label+extension+study+with+optional+narrow-band+ultraviolet+B.&amp;publication_year=2018&amp;journal=J+Am+Acad+Dermatol&amp;pages=1205-1207.e1&amp;doi=10.1016%2Fj.jaad.2018.02.023&amp;pmid=29438765" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. <em>Lancet</em> 2020;396:110-120.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)30609-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32653055/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000552724600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ruxolitinib+cream+for+treatment+of+vitiligo%3A+a+randomised%2C+controlled%2C+phase+2+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=110-120&amp;doi=10.1016%2FS0140-6736%2820%2930609-7&amp;pmid=32653055" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] trial involving adults with vitiligo. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] 75%, with improvement through week 52. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] mediators (e.g., CXCL10) in circulation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] clinically meaningful repigmentation. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use. <em>Clin Exp Dermatol</em> 1994;19:210-216.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2230.1994.tb01167.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8033378/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994NN18000003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dermatology+Life+Quality+Index+%28DLQI%29+%E2%80%94+a+simple+practical+measure+for+routine+clinical+use.&amp;publication_year=1994&amp;journal=Clin+Exp+Dermatol&amp;pages=210-216&amp;doi=10.1111%2Fj.1365-2230.1994.tb01167.x&amp;pmid=8033378" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Life Quality Index (DLQI [for adults]) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] physical symptoms such as itch and pain </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. <em>Br J Dermatol</em> 1995;132:942-949.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2133.1995.tb16953.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7662573/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1995RC52200015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+Children%E2%80%99s+Dermatology+Life+Quality+Index+%28CDLQI%29%3A+initial+validation+and+practical+use.&amp;publication_year=1995&amp;journal=Br+J+Dermatol&amp;pages=942-949&amp;doi=10.1111%2Fj.1365-2133.1995.tb16953.x&amp;pmid=7662573" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Dermatology Life Quality Index (CDLQI) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] physical symptoms such as itch and pain </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken, NJ: John Wiley, 1987.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Rubin+DB.+Multiple+imputation+for+nonresponse+in+surveys.+Hoboken%2C+NJ%3A+John+Wiley%2C+1987." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Gan EY, Eleftheriadou V, Esmat S, et al. Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference. <em>Pigment Cell Melanoma Res</em> 2017;30:28-40.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/pcmr.12561" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27864868/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393957200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Repigmentation+in+vitiligo%3A+position+paper+of+the+Vitiligo+Global+Issues+Consensus+Conference.&amp;publication_year=2017&amp;journal=Pigment+Cell+Melanoma+Res&amp;pages=28-40&amp;doi=10.1111%2Fpcmr.12561&amp;pmid=27864868" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Joshipura D, Plotnikova N, Goldminz A, et al. Importance of light in the treatment of vitiligo with JAK-inhibitors. <em>J Dermatolog Treat</em> 2018;29:98-99.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/09546634.2017.1339013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28581823/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423855400017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Importance+of+light+in+the+treatment+of+vitiligo+with+JAK-inhibitors.&amp;publication_year=2018&amp;journal=J+Dermatolog+Treat&amp;pages=98-99&amp;doi=10.1080%2F09546634.2017.1339013&amp;pmid=28581823" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Esmat SM, El-Tawdy AM, Hafez GA, et al. Acral lesions of vitiligo: why are they resistant to photochemotherapy? <em>J Eur Acad Dermatol Venereol</em> 2012;26:1097-1104.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1468-3083.2011.04215.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21851425/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000307555400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Acral+lesions+of+vitiligo%3A+why+are+they+resistant+to+photochemotherapy%3F&amp;publication_year=2012&amp;journal=J+Eur+Acad+Dermatol+Venereol&amp;pages=1097-1104&amp;doi=10.1111%2Fj.1468-3083.2011.04215.x&amp;pmid=21851425" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Narayan VS, Uitentuis SE, Bekkenk MW, Wolkerstorfer A. What is successful repigmentation in vitiligo from the point of view of patients? <em>Br J Dermatol</em> 2021;184:165-166.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjd.19422" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32726875/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000568590200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=What+is+successful+repigmentation+in+vitiligo+from+the+point+of+view+of+patients%3F&amp;publication_year=2021&amp;journal=Br+J+Dermatol&amp;pages=165-166&amp;doi=10.1111%2Fbjd.19422&amp;pmid=32726875" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Sanclemente G, Garcia JJ, Zuleta JJ, Diehl C, Correa C, Falabella R. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. <em>J Eur Acad Dermatol Venereol</em> 2008;22:1359-1364.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1468-3083.2008.02839.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18624857/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000259959900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+double-blind%2C+randomized+trial+of+0.05%25+betamethasone+vs.+topical+catalase%2Fdismutase+superoxide+in+vitiligo.&amp;publication_year=2008&amp;journal=J+Eur+Acad+Dermatol+Venereol&amp;pages=1359-1364&amp;doi=10.1111%2Fj.1468-3083.2008.02839.x&amp;pmid=18624857" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Chang H-C, Hsu Y-P, Huang Y-C. The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis. <em>J Am Acad Dermatol</em> 2020;82:243-245.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2019.07.108" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31408687/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000502846000050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+effectiveness+of+topical+calcineurin+inhibitors+compared+with+topical+corticosteroids+in+the+treatment+of+vitiligo%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2020&amp;journal=J+Am+Acad+Dermatol&amp;pages=243-245&amp;doi=10.1016%2Fj.jaad.2019.07.108&amp;pmid=31408687" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Bae JM, Jung HM, Hong BY, et al. Phototherapy for vitiligo: a systematic review and meta-analysis. <em>JAMA Dermatol</em> 2017;153:666-674.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamadermatol.2017.0002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28355423/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405476000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phototherapy+for+vitiligo%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2017&amp;journal=JAMA+Dermatol&amp;pages=666-674&amp;doi=10.1001%2Fjamadermatol.2017.0002&amp;pmid=28355423" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. <em>Arch Dermatol</em> 2007;143:578-584.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/archderm.143.5.578" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17519217/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000246477300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+double-blind+trial+of+treatment+of+vitiligo%3A+efficacy+of+psoralen-UV-A+therapy+vs+narrowband-UV-B+therapy.&amp;publication_year=2007&amp;journal=Arch+Dermatol&amp;pages=578-584&amp;doi=10.1001%2Farchderm.143.5.578&amp;pmid=17519217" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Yoshida A, Takagi A, Ikejima A, Takenaka H, Fukai T, Ikeda S. A retrospective study of 231 Japanese vitiligo patients with special reference to phototherapy. <em>Acta Dermatovenerol Croat</em> 2014;22:13-18.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24813836/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000336639800002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+retrospective+study+of+231+Japanese+vitiligo+patients+with+special+reference+to+phototherapy.&amp;publication_year=2014&amp;journal=Acta+Dermatovenerol+Croat&amp;pages=13-18&amp;pmid=24813836" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Khemis A, Fontas E, Moulin S, Montaudié H, Lacour JP, Passeron T. Apremilast in combination with narrowband UVB in the treatment of vitiligo: a 52-week monocentric prospective randomized placebo-controlled study. <em>J Invest Dermatol</em> 2020;140(8):1533-1537.e2.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jid.2019.11.031" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32004567/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000551035500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Apremilast+in+combination+with+narrowband+UVB+in+the+treatment+of+vitiligo%3A+a+52-week+monocentric+prospective+randomized+placebo-controlled+study.&amp;publication_year=2020&amp;journal=J+Invest+Dermatol&amp;pages=1533-1537.e2&amp;doi=10.1016%2Fj.jid.2019.11.031&amp;pmid=32004567" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Fontas E, Montaudié H, Passeron T. Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: a 24-week prospective randomized placebo-controlled study. <em>J Eur Acad Dermatol Venereol</em> 2021;35:1725-1729.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/jdv.17331" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33931900/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000649840100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oral+gliadin-protected+superoxide+dismutase+in+addition+to+phototherapy+for+treating+non-segmental+vitiligo%3A+a+24-week+prospective+randomized+placebo-controlled+study.&amp;publication_year=2021&amp;journal=J+Eur+Acad+Dermatol+Venereol&amp;pages=1725-1729&amp;doi=10.1111%2Fjdv.17331&amp;pmid=33931900" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. <em>J Eur Acad Dermatol Venereol</em> 2022;36:1507-1523.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/jdv.18129" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35366355/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000793254200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+humanistic+burden+of+vitiligo%3A+a+systematic+literature+review+of+quality-of-life+outcomes.&amp;publication_year=2022&amp;journal=J+Eur+Acad+Dermatol+Venereol&amp;pages=1507-1523&amp;doi=10.1111%2Fjdv.18129&amp;pmid=35366355" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Tsai H-R, Lu J-W, Chen L-Y, Chen T-L. Application of Janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta-analysis of clinical trials. <em>J Pers Med</em> 2021;11:279-279.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3390/jpm11040279" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33917069/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000643098200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Application+of+Janus+kinase+inhibitors+in+atopic+dermatitis%3A+an+updated+systematic+review+and+meta-analysis+of+clinical+trials.&amp;publication_year=2021&amp;journal=J+Pers+Med&amp;pages=279-279&amp;doi=10.3390%2Fjpm11040279&amp;pmid=33917069" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Lee JH, Kwon HS, Jung HM, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. <em>JAMA Dermatol</em> 2019;155:929-938.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamadermatol.2019.0696" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31141108/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000482438400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+outcomes+of+topical+calcineurin+inhibitor+therapy+for+patients+with+vitiligo%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2019&amp;journal=JAMA+Dermatol&amp;pages=929-938&amp;doi=10.1001%2Fjamadermatol.2019.0696&amp;pmid=31141108" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. <em>Blood</em> 2010;115:3109-3117.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2009-04-214957" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20130243/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000276689800017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms.&amp;publication_year=2010&amp;journal=Blood&amp;pages=3109-3117&amp;doi=10.1182%2Fblood-2009-04-214957&amp;pmid=20130243" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Hamzavi I, Rosmarin D, Harris JE, et al. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: descriptive subgroup analyses from a phase 2, randomized, double-blind trial. <em>J Am Acad Dermatol</em> 2022;86:1398-1401.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaad.2021.05.047" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34089797/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000830075500020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+ruxolitinib+cream+in+vitiligo+by+patient+characteristics+and+affected+body+areas%3A+descriptive+subgroup+analyses+from+a+phase+2%2C+randomized%2C+double-blind+trial.&amp;publication_year=2022&amp;journal=J+Am+Acad+Dermatol&amp;pages=1398-1401&amp;doi=10.1016%2Fj.jaad.2021.05.047&amp;pmid=34089797" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">Costin G-E, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. <em>FASEB J</em> 2007;21:976-994.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1096/fj.06-6649rev" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17242160/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245650400003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+skin+pigmentation%3A+melanocytes+modulate+skin+color+in+response+to+stress.&amp;publication_year=2007&amp;journal=FASEB+J&amp;pages=976-994&amp;doi=10.1096%2Ffj.06-6649rev&amp;pmid=17242160" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 19, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2211886" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">New Hope for Patients with Vitiligo</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">L. Eidsmo</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 18, 2023</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2215181" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Corning, New York</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887484/anesthesiology-generalist-starting-package-640k-corning-ny-/?query=fjwp&amp;rid=899">Anesthesiology - Generalist | Starting Package $640K (Corning, NY)</a></div></div><div class="nejm-widget_item"><div><span> Huntington, New York</span></div><div><span>Urology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/830572/men-s-health-urology-physician-huntington-ny/?query=fjwp&amp;rid=3059">Men's Health Urology Physician, Huntington, NY</a></div></div><div class="nejm-widget_item"><div><span> Washington State</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/875822/outpatient-family-medicine-central-washington-325-000-year-one/?query=fjwf&amp;rid=5263">Outpatient Family Medicine | Central Washington | $325,000 Year One</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885424/physician-internal-medicine/?query=fjwf&amp;rid=385607">Physician - Internal Medicine</a></div></div><div class="nejm-widget_item"><div><span> Cleveland, Ohio</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890366/family-medicine-physician-250000-00/?query=fjwf&amp;rid=346908">Family Medicine Physician - $250000.00</a></div></div><div class="nejm-widget_item"><div><span> Murray, Utah</span></div><div><span>Surgery, Plastic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886045/plastic-and-reconstructive-surgeon/?query=fjwf&amp;rid=751">Plastic &amp; Reconstructive Surgeon</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2118828&amp;pubId=41284316&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6f09145da00fb-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6f09145da00fb-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6f09145da00fb-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$975529111$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$975529111$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$975529111$--></div></div><div class="mlt-body"><!--?lit$975529111$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$975529111$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$975529111$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$975529111$-->Sep 21, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2309427?query=recirc_Semantic" target="_self">Skin Cancer after Ruxolitinib or Belumosudil</a></div><div class="mlt-article-authors"><!--?lit$975529111$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$975529111$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$975529111$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$975529111$-->Jun 15, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2202318?query=recirc_Semantic" target="_self">Variant <em>STAT4</em> and Response to Ruxolitinib in an Autoinflammatory Syndrome</a></div><div class="mlt-article-authors"><!--?lit$975529111$-->H. Baghdassarian and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$975529111$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$975529111$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$975529111$-->Jul 15, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2033122?query=recirc_Semantic" target="_self">Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease</a></div><div class="mlt-article-authors"><!--?lit$975529111$-->R. Zeiser and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$975529111$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$975529111$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$975529111$-->Jul 13, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2304157?query=recirc_Semantic" target="_self">Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil</a></div><div class="mlt-article-authors"><!--?lit$975529111$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$975529111$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$975529111$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$975529111$-->May 07, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1917635?query=recirc_Semantic" target="_self">Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease</a></div><div class="mlt-article-authors"><!--?lit$975529111$-->R. Zeiser and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2118828?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2118828" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2118828.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2118828"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp2212939" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Atrial Fibrillation — What Is It and How Is It Treated?</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2208687" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2118828_f0.jpg"><img src="/cms/10.1056/NEJMoa2118828/asset/dbb9ea1e-44ab-468b-a14e-93993bfebe48/assets/images/large/nejmoa2118828_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Safety Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary and Key Secondary Efficacy End Points (Double-Blind Period; Modified Intention-to-Treat Population).<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events during the Double-Blind Period and Open-Label Treatment Extension Period.</div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/387/16" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 387 No. 16</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 20, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2208687" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J. Kjaergaard and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 20, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2205650" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">L. Leelarathna and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 20, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2208686" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Oxygen Targets in Comatose Survivors of Cardiac Arrest</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">H. Schmidt and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2118828%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2118828&amp;pubId=41284316&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2118828%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2118828&amp;pubId=41284316&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id06434404798871258" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6f09145da00fb-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6f09145da00fb-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6f09145da00fb-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6f09145da00fb-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6f09145da00fb-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6f09145da00fb-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6f09145da00fb-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6f09145da00fb-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6f09145da00fb-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6f09145da00fb-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6f0913da400fb',t:'MTc0OTUzODI4MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6f0913da400fb&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><zhf-lepratgvmzpl></zhf-lepratgvmzpl><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2118828?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-transactionid="xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" id="captureIFrame_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" target="captureIFrame_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="capture_screen"><input id="capture_signIn_js_version_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="js_version"><input id="capture_signIn_transactionId_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" type="hidden" class="capture_transactionId_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="capture_transactionId"><input id="capture_signIn_form_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="form"><input id="capture_signIn_flow_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="flow"><input id="capture_signIn_client_id_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="client_id"><input id="capture_signIn_redirect_uri_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="redirect_uri"><input id="capture_signIn_response_type_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="response_type"><input id="capture_signIn_flow_version_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="flow_version"><input id="capture_signIn_settings_version_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="settings_version"><input id="capture_signIn_locale_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="locale"><input id="capture_signIn_recaptcha_version_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_xujkgmig4o379g4cczc3idkac4iv9ohdq7shjzwm" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>